Effect of SARS-CoV-2 infection on IVF/ICSI-ET outcomes: A propensity score-matched cohort study

Effect of SARS-CoV-2 infection on IVF/ICSI-ET outcomes: A propensity score-matched cohort study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Effect of SARS-CoV-2 infection on IVF/ICSI-ET outcomes: A propensity score-matched cohort study Yanhui Li, Xiaofang Ding, Dan Luo, Tao Li, Lin Liu, Bingjie Li, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3172915/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: The SARS-CoV-2 virus is continually evolving, and the worldwide epidemic is still ongoing. There is conflicting evidence regarding how SAS-CoV-2 infection affects the outcomes of assisted reproductive technology (ART). The aim of the current study was to investigate whether the outcomes of in vitro fertilization (IVF) treatment were affected during the acute period of SARS-CoV-2 infection or immediately after recovery from COVID-19. Methods: In this retrospective cohort study, SARS-CoV-2-infected couples who underwent IVF treatment at Wuhan Union Hospital within the first three months following the lifting of the pandemic policy in mainland China were propensity-score matched (PSM) to uninfected couples who received IVF during the dynamic COVID-zero policy. Following matching, 358 and 698 patients were assigned to the SARS-CoV-2-infected and uninfected groups, respectively. The laboratory and clinical outcomes of the two groups were compared. Results: The average number of oocytes retrieved, mature oocyte rates, normal fertilization rates, abnormal fertilization rates, and cleavage rates did not differ significantly between the two groups. The blastocyst formation rates were considerably lower in the infected group than in the uninfected group. Stratification by time from SARS-CoV-2 infection to oocyte retrieval (≤ 30, 31-60, 61-90 and ≥90 days) revealed that both blastocyst formation and available blastocyst rates were significantly decreased when oocyte retrieval was performed 31-60 days after SARS-CoV-2 infection. However, after the first embryo transfer cycle, there were no significant differences in the rates of embryo implantation, biochemical pregnancy, clinical pregnancy or early abortion between the two matched cohorts. Conclusion: SARS-CoV-2 infection had no effect on clinical outcomes after the first embryo transfer cycle; however, the blastocyst formation rate was significantly lower in couples who underwent IVF treatment 31-60 days after SARS-CoV-2 infection, indicating that SARS-CoV-2 infection may still impair embryo developmental potential. COVID-19 IVF SARS-CoV-2 infertility embryo pregnancy Figures Figure 1 Figure 2 Background The World Health Organization (WHO) declared that COVID-19 was no longer a public health emergency of international concern (PHEIC) on May 5, 2023. SARS-CoV-2 is still evolving [ 1 ], resulting in new cases and reinfections in the population [ 2 – 4 ]. As SARS-CoV-2 is a new virus, we still need to improve our understanding of it, especially its effects on human reproduction and assisted reproductive technology (ART) [ 5 ] Currently, it is believed that the SARS-CoV-2 virus damages cells or tissues by infecting and replicating in cells, which requires the expression of SARS-CoV-2 receptors, such as angiotensin converting enzyme 2 (ACE2), basigin (BSG), transmembrane serine protease 2 (TMPRSS2) and cathepsin L (CTSL) [ 6 , 7 ]. It is noteworthy that all the aforementioned viral receptor mRNAs are expressed in most of the human female reproductive tract, including the ovaries (including follicular granulosa cells) [ 8 ] and endometrium [ 9 ]. A few studies have also shown that ACE2, BSG, and/or TMPRSS2 genes and proteins are expressed in human oocytes, fertilized eggs, and blastocysts [ 10 – 12 ]. Therefore, the effects of SARS-CoV-2 infection on the pregnancy outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) have been the focus of attention for ART staff and patients. A retrospective study from Israel showed that IVF treatment within one year after SARS-CoV-2 infection did not affect the pregnancy outcomes after fresh embryo transfer. It should be noted that this study did not mention whether or not the control group was thoroughly screened for SARS-CoV-2 infection. [ 13 ]. However, several studies have found that the rate of high-quality embryos [ 14 ] and retrieved oocytes [ 15 ] was decreased in patients who underwent IVF treatment after being infected with SARS-CoV-2. Another study discovered that when only the male partner was infected with SARS-CoV-2, the blastocyst formation rate was reduced, even though the IVF procedure was performed more than 4 months after SARS-CoV-2 infection [ 16 ]. It should be noted that all of these studies had small sample sizes and did not conduct stratified analyses of the time from SARS-CoV-2 infection to oocyte retrieval. As a result, the impact of SARS-CoV-2 infection on IVF treatment outcomes remains unclear. The clinical and laboratory results of patients who underwent IVF treatment during the acute infection period, in particular, were mostly from case reports [ 17 , 18 ]. Due to China's effective and strict epidemic prevention and control policy, ART services in mainland China were carried out in a nonepidemic state from the beginning of 2020 to November 2022. However, with the attenuated pathogenicity of the omicron subvariants and increasing vaccination coverage, the dynamic zero-COVID policy was terminated in mainland China on December 7, 2022 [ 19 ]. A wave of SARS-CoV-2 infections was reported in mainland China from December 2022 to January 2023 [ 4 , 20 ]. This infection wave was mainly caused by the SARS-CoV‐2 omicron variants BF.7 and BA.5.2 [ 21 ]. During this time, our center also treated more SARS-CoV-2-infected couples, providing a good observation sample. Thus, in the present study, we collected IVF data from SARS-CoV-2-infected couples who underwent IVF treatment from December 7, 2022, to March 7, 2023, in our center to evaluate the effects of SARS-CoV-2 infection on embryo development and IVF clinical outcomes. Materials and methods Study population and design In this retrospective cohort study, all couples who underwent their first or second cycle of IVF or ICSI treatment at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from December 7, 2022, to March 7, 2023, were enrolled. Couples in which both partners were infected with SARS-CoV-2 on or before the trigger day (based on PCR tests for detecting SARS-CoV-2 RNA from nasopharyngeal swabs) and the female partner was aged between 21 and 50 years were included as the SARS-CoV-2-positive group. To avoid the possibility of unknown and asymptomatic incubation periods, the current study also enrolled all couples who underwent their first or second cycle of IVF or ICSI treatment in our center from June 1, 2021, to November 30, 2022 (during which the dynamic zero-COVID policy was implemented in mainland China). Couples with no history of SARS-CoV-2 infection and in which the female partner was aged 21–50 years were included as the SARS-CoV-2-negative (control) group. Couples in both groups underwent at least two PCR tests to detect SARS-CoV-2 RNA during controlled ovarian stimulation (COS), namely, before COS and on the trigger day. Pulmonary computed tomography was also performed to rule out lung lesions. Moreover, a careful medical history was taken and a COVID-19 questionnaire survey was performed for all patients before the initiation of COS. The following patients were excluded: (a) patients who were missing important information; (b) patients who were lost to follow-up; (c) patients who used donor eggs or sperm; (d) patients who underwent total or partial oocyte freezing; and (e) patients who underwent preimplantation genetic testing cycles. Propensity score matching between the infected group and the uninfected group was performed at a ratio of 1:2 to create groups that had comparable characteristics. The present study was approved by the Ethical Committee of Union Hospital (no. 2023-S0462), and individual consent for this retrospective analysis was waived. Ovarian stimulation In this study, most patients underwent the gonadotropin-releasing hormone (GnRH) agonist protocol or the GnRH antagonist protocol. A few patients underwent the clomiphene-primed ovarian stimulation (CPOS) luteal phase stimulation protocol. For the GnRH agonist protocol, tripreilin acetate was injected at 0.05 mg/d (Ferring Pharmaceuticals, German) at the middle luteal stage of the previous cycle for pituitary downregulation. When the downregulation standard was reached (serum luteinizing hormone level < 5 IU/L, serum estradiol level < 50 pg/ml, endometrial thickness < 10 mm, no functional ovarian cysts), urine follicle-stimulating hormone (uFSH) (Zhuhai Lizon Pharmaceutical, China) or recombinant follicle-stimulating hormone (rFSH) (Merck Serono, Switzerland) was initiated with at 150–225 U. Adjustments were made according to the ovarian response. For the GnRH antagonist protocol, ovarian stimulation was initiated with 150–225 IU uFSH or rFSH daily. The GnRH antagonist (0.25 mg, Cetrotide, 0.25 mg SC; Merck-Serono) was administered daily to prevent premature ovulation if at least one of the following criteria was met: at least one follicle measured > 14 mm; an E2 serum level > 500 pg/mL; or an LH serum level > 10 IU/L. When bilateral ovaries had ≥ 2 ~ 3 follicles with diameters > 18 mm, 10000 IU human chorionic gonadotropin (hCG) (Lizhu Pharmaceutical Trading Co., People’s Republic of China) or 250 mg Ovidrel (Merck Serono S.p.A., Modugno, Italy) was administered to trigger the final maturation of the oocytes. Transvaginal oocyte retrieval was performed under ultrasound guidance 34–36 h after hCG administration. Fertilization and embryo evaluation Fertilization was achieved by IVF or ICSI according to the male partner’s sperm quality. For IVF fertilization, approximately 20,000 motile sperm were added to each oocyte. If the total number of motile sperm was < 5×106/ml or the proportion of normal sperm was < 1%, ICSI was performed. The presentation of 2 pronuclei (2PN) 16–18 h after insemination was regarded as normal fertilization. After 72 h of in vitro culture, embryos were evaluated according to the evenness of blastomeres and the percentage of embryo fragmentation [ 22 ]. Embryos comprising 6–8 cells and those of grade 1 or 2 were regarded as top-quality embryos. Some of the embryos were cultured into blastocysts for an additional 2–4 days. Blastocysts were evaluated using Gardner's grading scale [ 23 ] Throughout the study period, the staff at the center, as well as the culture conditions and culture medium in the embryo laboratory, remained unchanged. Fresh and frozen embryo transfer Embryo transfer was performed under abdominal ultrasound guidance, with a maximum of 2 cleavage-stage embryos or blastocysts transferred each time. The “freeze-all” strategy was employed for couples in the acute stage of SARS-CoV-2 infection. If the couples met the criteria for fresh embryo transfer, embryo transfer was performed on Day 3, 5 or 6 after oocyte retrieval. The surplus embryos were further cultured in G2-plus medium (Vitrolife, Gothenburg, Sweden) up to Day 5–6 until they reached the blastocyst stage, and the available blastocysts were frozen by vitrification. For frozen embryo transfer, most of the enrolled patients underwent hormone replacement cycles to prepare the endometrium. The details of the vitrification procedure and endometrial preparation were described previously [ 24 ]. SARS-CoV-2 nucleic acid tests Real-time polymerase chain reaction (RT‒PCR) (Mingde Biotechnology Co., Ltd, Wuhan, China) was carried out to detect the presence of SARS-CoV-2 RNA in the specimens collected from nasopharyngeal swabs. The open reading frame 1ab (ORF1ab) and N genes of SARS-CoV-2 were the target genes for RT–PCR. A cycle threshold (Ct) of less than 37 denoted positive SARS-CoV-2 findings. Outcome measures The important quality control indices during COS and in vitro embryo culture and pregnancy outcomes in the first trimester were analyzed and compared between the two groups. The primary outcome measure was the clinical pregnancy rate after the first embryo transfer cycle. The secondary outcome measures included the number of oocytes retrieved, the number of mature oocytes, the number of normal fertilizations, the blastocyst formation rate, the number of available embryos, early pregnancy loss, etc. The above measures were calculated according to our previous report [ 24 ]. The high-quality embryo rate was defined as the number of high-quality embryos on Day 3 divided by the number of normally fertilized cleavage embryos. The blastocyst formation rate was defined as the number of blastocysts formed divided by the number of normally fertilized oocytes. The available blastocyst rate was defined as the number of blastocysts for cryopreservation and transfer divided by the number of normally fertilized oocytes. A clinical pregnancy was defined as the identification of a gestational sac 4 weeks after embryo transfer. A biochemical pregnancy was defined as serum β-hCG level > 5 mU/mL. The denominator of the clinical pregnancy rate and biochemical pregnancy rate was the number of embryo transfer cycles. Statistical analyses Kolmogorov–Smirnov or Shapiro–Wilk normality tests were used for all continuous variables. Variables with a normal distribution are presented as \(\stackrel{-}{x}\pm s\) . Statistical comparison was performed by Student’s t test. Variables that did not conform to a normal distribution are given as the median + interquartile range (IQR), and differences between groups were compared by the Mann‒Whitney U test. Categorical variables are presented as the n (%), and statistical comparisons were performed using the chi-square test. Standard propensity score matching was conducted using nearest neighbor matching with a caliper of 0.02. The following baseline characteristics were matched without replacement at a ratio of 1:2: female age (years), female body mass index (BMI, kg/m2), basal follicle stimulating hormone level (FSH, mIU/mL), basal anti-Müllerian hormone level (AMH, ng/mL), infertility type (primary or secondary), infertility duration (years), infertility cause, insemination method (IVF or ICSI), and COS protocol (GnRH agonist protocol, GnRH antagonist protocol, and other protocols). Women who were not matched were excluded from the analyses. Two-tailed P values < 0.05 were considered statistically significant. The Statistical Package for Social Sciences software (SPSS Inc., Version 24.0, Chicago) and R version 4.1.0 (R Core Team, Vienna, Austria) were used for data analyses. Results Among those who underwent IVF/ICSI at our center between December 7, 2022 and March 7, 2023, a total of 386 couples met the above inclusion and exclusion criteria, and both partners were infected with SARS-CoV-2 on or before the trigger day. A total of 2660 uninfected patients who underwent IVF/ICSI between June 1, 2021 and November 30, 2022, and met the exclusion and inclusion criteria were selected as controls. After propensity score matching was performed, 358 patients were included in the infected group, and 698 patients were included in the uninfected group (Figure. 1). The baseline demographic characteristics of the couples after matching are presented in Table 1. No significant differences were found with regard to any baseline characteristics between the 2 groups (P>0.05). The distribution of propensity scores and standard differences before and after matching between the groups are presented in Figure. 2. The overlap in density represented the balance of the distribution between the two groups, which indicated that the patients were well matched after propensity score matching. The clinical manifestations of the 358 matched female partners after infection with SARS-CoV-2 are presented in Supplementary Table 1. A total of 80.17% of the women (287 women) had mild COVID-19, with fever, headache, muscle aches, sore throat, and other symptoms but no lung imaging changes [25]. A total of 9.5% of the women (34 women) had moderate COVID-19, and they had typical lung imaging changes in addition to the clinical symptoms described above. A total of 10.33% of the women (37 women) were asymptomatic and were diagnosed by SARS-CoV-2 mRNA screening during IVF treatment. None of the patients were diagnosed with severe disease [26]. For the oocyte and embryo outcomes, there were no significant differences between the two groups in the average number of oocytes retrieved, the mature oocyte rates, the normal fertilization rates, the abnormal fertilization rates, and the cleavage rates. However, compared with the uninfected (control) group, the blastocyst formation rate in the infected group was significantly decreased [73.33% (IQR 50.00%-92.31%) vs. 66.67% (IQR 50.00%-87.5%); p<0.05], and the high-quality embryo rate on Day 3 also showed a downward trend (Table 2). This indicates that embryo developmental potential may be affected in SARS-CoV-2 patients. The infected group was stratified into subgroups by the interval from SARS-CoV-2 infection to oocyte retrieval (30 days, 31-60 days, 61-90 days, and > 90 days). Subgroup analysis revealed that couples who underwent IVF 31-60 days after SARS-CoV-2 infection had significantly lower rates of high-quality embryos on Day 3, blastocyst formation and available blastocysts than the other three subgroups and the uninfected control group. However, blastocyst formation was not significantly affected in patients who underwent IVF within 30 days or more than 60 days after SARS-CoV-2 infection (Table 3). To exclude possible confounding factors of the blastocyst formation rate, we further conducted a linear-regression analysis including patient age, body mass index, ovarian stimulation protocol, fertilization method, type of infertility, cause of infertility, number of mature oocytes, and D3 high-quality embryo rate. The results also suggested that SARS-CoV-2 infection, together with female age and the D3 high-quality embryo rate, was a significant predictor of the blastocyst formation rate (Supplementary Table 2). More notably, the linear regression analysis model for blastocyst formation rate stratified by the time from SARS-CoV-2 infection to oocyte retrieval further strengthened the univariate results, with 31-60 days after SARS-CoV-2 infection remaining a significant variable (p<0.001, 95% CI -0.211 - -0.074). On the other hand, IVF within 30 days or more than 60 days following SARS-CoV-2 infection was not a significant predictor of the blastocyst formation rate (Table 4). For clinical pregnancy outcomes, 290 couples in the infected group (99 couples underwent fresh embryo transfer) and 607 couples in the matched uninfected group (139 couples underwent fresh embryo transfer) completed the first cycle of embryo transfer. There was no significant difference in embryo implantation rate (54.88% vs. 49.54%), biochemical pregnancy rate (68.62% vs. 65.56%), clinical pregnancy rate (58.62% vs. 57.01%), or early abortion rate (10.59% vs. 10.98%) after the first cycle of embryo transfer between the two groups (Table 5). Discussion In the current study, we enrolled SARS-CoV-2-infected couples who underwent IVF treatment during the first three months after the public health control measures were adjusted in mainland China; these infected couples were matched to uninfected couples who underwent IVF treatment during the period of the dynamic zero-COVID-19 policy in mainland China. IVF treatment outcomes were compared between the two groups, and the results showed that the blastocyst formation and available blastocyst rates were significantly decreased in couples who underwent IVF treatment 31–60 days after SARS-CoV-2 infection, implying that we should remain concerned about the potential adverse effects of SARS-CoV-2 on embryo development. Several pathogens, such as hepatitis virus, human immunodeficiency virus, and Zika virus [ 27 ], may have variable impacts on the physiopathology of the reproductive organs, leading to infertility or poor ART outcomes [ 28 ]. Therefore, when the new SARS-CoV-2 virus emerged and spread globally, researchers focused on the impact of infection with this virus on human reproduction and ART outcomes [ 5 ]. The effects of SARS-CoV-2 infection on the laboratory and clinical outcomes of ART have not yet been consistently documented in the literature [ 14 , 29 – 31 ]. An unclear infection status, the inability to correctly measure the time between SARS-CoV-2 infection and ART treatment, and the absence of a stratification analysis on the time of oocyte retrieval relative to SARS-CoV-2 infection could all be contributing factors. For instance, the pregnancy outcomes of patients who underwent IVF treatment before and during the COVID-19 pandemic were compared in the retrospective studies of Huri et al. [ 30 ] and Rageh et al. [ 32 ], but the authors failed to clarify whether the cohorts who underwent IVF treatment during the COVID-19 pandemic were infected with SARS-CoV-2. The largest retrospective analysis of IVF outcomes in SARS-CoV-2 patients to date was reported in a 2022 report from Israel [ 13 ]. By comparing the IVF data of 121 patients previously infected with COVID-19 and 121 uninfected patients, the researchers discovered that IVF treatment within one year after SARS-CoV-2 infection had no effect on the outcomes of fresh embryo transfer. Nonetheless, it should be highlighted that it was not made clear in this study whether the control group underwent rigorous testing for SARS-CoV-2 infection [ 13 ]. Furthermore, in another study, the same group reported that patients with previous SARS-CoV-2 infection who underwent frozen embryo transfer cycles with oocytes retrieved prior to infection had lower pregnancy rates, notably those who had recovered fewer than 60 days before embryo transfer [ 33 ]. More importantly, the clinical outcomes of patients who underwent IVF during the acute period of SARS-CoV-2 infection are mostly described in case reports [ 17 , 18 ]. As a result, more research on the laboratory and clinical outcomes of ART in patients during and after SARS-CoV-2 infection is needed. In the current study, we performed propensity score matching to eliminate the imbalance of the number and distribution of participants between groups. Thus, our findings are much more convincing and reliable. Notably, in the current study, the blastocyst formation rates were significantly lower in couples who underwent IVF treatment 31–60 days after SARS-CoV-2 infection than in uninfected couples [50% (31.67%, 0.83.33%) vs. 73.33% (50.00%, 92.31%)] and were also significantly lower than the benchmark value recommended by the Vienna consensus, which suggests that the blastocyst formation rate should be above 60% [ 34 ]. The rate of blastocyst formation is an essential key performance indicator (KPI) in embryo laboratories. This KPI is influenced not only by the whole culture system [ 34 ] but also by female age [ 35 ], oocyte quality [ 36 ] and male sperm quality [ 37 , 38 ]. We thoroughly checked the post of embryo laboratory staff and the culture medium used for embryo culture and discovered that the above conditions were constant over the study period. Furthermore, there was no difference in the age of female partners across subgroups and the uninfected group. As a result, we assumed that the lower rate of blastocyst formation in the subgroup who underwent IVF treatment 31–60 days after SARS-CoV-2 infection was due to SARS-CoV-2 infection. Further linear retrospective analysis in our current study supported this conclusion. The negative effects of SARS-CoV-2 infection on embryo developmental potential have already been reported in several small-sample retrospective studies. An observational study reported that the proportion of high-quality embryos in patients decreased after SARS-CoV-2 infection, according to a self-controlled analysis of 9 patients [ 14 ]. Another study found that couples undergoing IVF treatment in which only the male partner was infected with the SARS-CoV-2 virus also had lower blastocyst formation rates [ 16 ]. However, a recent prospective cohort study by Chen et al. [ 39 ] included 706 couples who underwent IVF treatment between December 1, 2022, and January 11, 2023, when China's epidemic control policy was initially relaxed. Surprisingly, they reported that the infected patients had more normally fertilized oocytes than the noninfected patients, but no significant differences were observed between the two groups in oocyte outcomes, such as the number of oocytes retrieved, oocyte maturation rate and normal fertilization rate (these observations were similar to the results obtained in the current study). It is crucial to note, however, that the time of oocyte retrieval relative to the time of SARS-CoV-2 infection was less than 2 weeks in most patients in their study, and they also did not disclose the blastocyst formation rates or clinical pregnancy outcomes of the infected women. The SARS-CoV-2 host receptors ACE2 and TMPRSS2 have been found in ovarian tissues [ 40 ], oocyte cumulus complexes [ 41 ], oocytes [ 42 ], and blastocysts [ 10 , 43 ]. An in vitro study further revealed that fluorescent reporter virions pseudotyped with SARS-CoV-2 Spike (S) glycoprotein can infect trophectoderm cells. However, SARS-CoV-2 mRNA has yet to be found in infected patients' follicular fluid [ 44 ], granular cells [ 18 ], oocytes [ 45 ], or semen [ 46 ]. Therefore, we believe that the decrease in the blastocyst formation rate in couples 31–60 days after SARS-CoV-2 infection observed in the current study was more likely due to indirect effects of SARS-CoV-2 infection. The decreased blastocyst formation rate may be attributed to several potential causes. First, the SARS-CoV-2 virus can induce an upregulation of proinflammatory cytokines and systemic oxidative stress in infected individuals [ 47 , 48 ], which may damage the human gonads. It has been reported that the menstrual cycles of women and semen parameters of men significantly changed approximately 2 months after SARS-CoV-2 infection [ 49 , 50 ]. Approximately 30 days after SARS-CoV-2 infection, these damaging effects on the gonads reach their peak [ 51 ]. Studies have shown that sperm progressive motility and morphology are closely connected with the blastocyst formation rate [ 37 , 52 ]. In the current study, we also found a significant increase in the proportion of early rescue ICSI in the 31–60 days post-SARS-CoV-2 infection.. Second, during SARS-CoV-2 infection, the body develops neutralizing antibodies, which peak 3–4 weeks after infection [ 53 , 54 ]. A previous study showed that anti-SARS-CoV-2 IgG antibodies can be detected in follicular fluid; in an in vitro experiment, the expression of steroidal acute regulatory protein (StAR), estrogen receptor β (Erβ) and vascular endothelial growth factor (VEGF) in granulosa cells was significantly reduced after the stimulation of follicular fluid from recovered COVID-19 patients. It is suggested that SARS-CoV-2 infection affects the follicular microenvironment and may have adverse effects on female reproductive outcomes. Although the clinical outcomes of first-cycle embryo transfer in couples who underwent IVF treatment within 31–60 days of SARS-CoV-2 infection were unaffected, it remains to be seen whether the decreased blastocyst formation rate in these patients will have an effect on the cumulative live birth rate. Furthermore, long-term follow-up is required to clarify the offspring safety of IVF treatment at different times following SARS-CoV-2 infection. There are some limitations in this study. First, it was a retrospective study, so various confounding factors are likely to affect the study results. The PSM approach was used in the current study, and patients were matched for 9 basic characteristics at a ratio of 1:2 to exclude the influence of confounding factors as much as possible. However, some known or unknown confounding factors may still affect the statistical results. Second, to rule out the possibility of unknown and asymptomatic incubation periods, the current study included patients undergoing IVF treatment at different times as controls, resulting in the proportion of patients completing the first embryo transfer being different between the two groups, which may have an impact on the comparison of the clinical outcomes of the patients in the two groups. Third, due to the short follow-up period in the current study, data on the live birth rate of SARS-CoV-2-infected and uninfected patients undergoing IVF were lacking. In the future, we will continue to follow up with our study cohort to determine the impact of SARS-CoV-2 infection on the cumulative live birth rate. Finally, there were no severe COVID-19 patients included in this study, which means that the results may not accurately represent the overall impact of SARS-CoV-2 infection on IVF treatment. In conclusion, the results of the current study showed that SARS-CoV-2 infection had no effect on the clinical pregnancy outcomes after the first embryo transfer cycle, but the couples who underwent IVF treatment 31–60 after SARS-CoV-2 infection had significantly lower blastocyst formation and blastocyst availability rates. Prospective studies are still needed to confirm these findings. However, until more definitive evidence is available, it is appropriate to postpone IVF beyond 2 months, if possible, in couples with SARS-CoV-2 infection. Abbreviations ART: assisted reproductive technology; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; COVID-19: coronavirus disease 2019; IVF: in vitro fertilization; PSM: propensity-score matched; WHO: World Health Organization; PHEIC: public health emergency of international concern; ACE2: angiotensin converting enzyme 2; BSG: basigin (BSG); TMPRSS2: transmembrane serine protease 2; CTSL: cathepsin L; IVF/ICSI: in vitro fertilization/intracytoplasmic sperm injection; COS: controlled ovarian stimulation; GnRH: gonadotropin-releasing hormone; CPOS: clomiphene-primed ovarian stimulation; uFSH: urine follicle-stimulating hormone; rFSH: recombinant follicle-stimulating hormone; hCG: human chorionic gonadotropin; RT-PCR: Real-time polymerase chain reaction; IQR: interquartile range; BMI: body mass index; AMH: anti-Müllerian hormone; KPI: key performance indicator. Declarations Ethics approval and consent to participate This retrospective study was approved by the Medical Ethical Committee of Union Hospital (no. 2023-S0462), and individual consent for this retrospective analysis was waived. Consent for publication Not applicable Availability of data and materials The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Competing interests The authors declare that they have no competing interests. Funding This work was supported by Hubei Provincial Natural Science Foundation of China (No. 2022CFB243). Authors' contributions YL and HD conceived and designed the study. YL and HD contributed to acquisition of the data. YL and HD contributed to the analysis. YL, HD, YL, TL and BL contributed to the interpretation of the data. All authors made contributions to drafting and revising the article critically for important intellectual content. All authors approved the final version of the article to be published. Acknowledgements We would like to express our gratitude to Dr. Zhenyuan Chen for his statistical advice. We also would like to thank our colleagues at the Reproductive Medicine Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. References Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A: The evolution of SARS-CoV-2 . Nat Rev Microbiol 2023, 21 : 361-379. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, Coyle P, Yassine HM, Al-Khatib HA, Benslimane FM, et al: Protection against the Omicron Variant from Previous SARS-CoV-2 Infection . N Engl J Med 2022, 386 : 1288-1290. Vicentini M, Venturelli F, Mancuso P, Bisaccia E, Zerbini A, Massari M, Cossarizza A, De Biasi S, Pezzotti P, Bedeschi E, et al: Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022 . Eur Surveill 2023, 28 : 2200494. Ye Y: China's rolling COVID waves could hit every six months - infecting millions . Nature 2023, 618 : 442-443. Ata B, Vermeulen N, Mocanu E, Gianaroli L, Lundin K, Rautakallio-Hokkanen S, Tapanainen JS, Veiga A: SARS-CoV-2, fertility and assisted reproduction . Hum Reprod Update 2023, 29 : 177-196. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor . Cell 2020, 181 : 271-280.e278. Wang Y, Wang Y, Luo W, Huang L, Xiao J, Li F, Qin S, Song X, Wu Y, Zeng Q, et al: A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells . Int J Med Sci 2020, 17 : 1522–1531. Stanley KE, Thomas E, Leaver M, Wells D: Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues . Fertil Steril 2020, 114 : 33-43. Henarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A, Pellicer A, Diaz-Gimeno P: SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle . Fertil Steril 2020, 114 : 223-232. Essahib W, Verheyen G, Tournaye H, Velde HVD: SARS-CoV-2 host receptors ACE2 and CD147 (BSG) are present on human oocytes and blastocysts . J Assist Reprod Genet 2020, 37 : 2657–2660. Weatherbee BAT, Glover DM, Zernicka-Goetz M: Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester . Open Biol 2020, 10 : 200162. Virant-Klun I, Strle F: Human Oocytes Express Both ACE2 and BSG Genes and Corresponding Proteins: Is SARS-CoV-2 Infection Possible? Stem Cell Rev Rep 2021, 17 : 278-284. Youngster M, Avraham S, Yaakov O, Landau Rabbi M, Gat I, Yerushalmi G, Sverdlove R, Baum M, Maman E, Hourvitz A, Kedem A: IVF under COVID-19: treatment outcomes of fresh ART cycles . Hum Reprod 2022, 37 : 947-953. Orvieto R, Segev-Zahav A, Aizer A: Does COVID-19 infection influence patients' performance during IVF-ET cycle?: an observational study . Gynecol Endocrinol 2021, 37 : 895-897. Herrero Y, Pascuali N, Velázquez C, Oubiña G, Hauk V, de Zúñiga I, Peña MG, Martínez G, Lavolpe M, Veiga F, et al: SARS-CoV-2 infection negatively affects ovarian function in ART patients . Biochim Biophys Acta Mol Basis Dis 2022, 1868 : 166295. Wang M, Hu J, Huang B, Yang Q, Liu S, Li Z, Yang L, Xi Q, Zhu L, Jin L: Investigating the impact of SARS-CoV-2 infection on basic semen parameters and in vitro fertilization/intracytoplasmic sperm injection outcomes: a retrospective cohort study . Reprod Biol Endocrinol 2022, 20 : 46. Demirel C, Tulek F, Celik HG, Donmez E, Tuysuz G, Gökcan B: Failure to Detect Viral RNA in Follicular Fluid Aspirates from a SARS-CoV-2-Positive Woman . Reprod Sci 2021, 28 : 2144-2146. Boudry L, Essahib W, Mateizel I, Velde HVD, De Geyter D, Piérard D, Waelput W, Uvin V, Tournaye H, De Vos M, De Brucker M: Undetectable viral RNA in follicular fluid, cumulus cells, and endometrial tissue samples in SARS-CoV-2-positive women . Fertil Steril 2022, 117 : 771–780. Liu P, Xu J: Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022–January 2023 . J Infect 2023, 86 : e84–86. Zeng X, Xie Y, Yang X, Peng Z, Tang J, Yang L, Lin S, Han J, Zhang Y, Wang D: SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023 . China CDC Wkly 2023, 5 : 152-158. Sun Y, Wang M, Lin W, Dong W, Xu J: Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China . J Biosaf Biosecur 2023, 5 : 14–20. Veeck LL: Oocyte assessment and biological performance . Ann N Y Acad Sci 1988, 541 : 259–274. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB: Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer . Fertil Steril 2000, 73 : 1155-1158. Liu L, Li YH, Ding XF, Geng YH, Chen CY, Gao Y: Influence of blastocysts morphological score on pregnancy outcomes in frozen-thawed blastocyst transfers: a retrospective study of 741 cycles . J Huazhong Univ Sci Technolog Med Sci 2014, 34 : 750-754. Gandhi RT, Lynch JB, Del RC: Mild or moderate covid-19 . N Engl J Med 2020, 383 : 1757–1766. Berlin DA, Gulick RM, Martinez FJ: Severe Covid-19 . N Engl J Med 2020, 383 : 2451-2460. Block LN, Aliota MT, Friedrich TC, Schotzko ML, Mean KD, Wiepz GJ, Golos TG, Schmidt JK: Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model† . Biol Reprod 2020, 102 : 806-816. Carbone L, Conforti A, A. MAL, Cariati F, Vallone R, Raffone A, Buonfantino C, Palese M, Mascia M, I. GRD, et al: The negative impact of most relevant infections on fertility and assisted reproduction technology . Minerva Obstet Gynecol 2021, 74 : 83–106. Kabalkin Y, Bentov Y, Gil M, Beharier O, Jaber S, Moav-Zafrir A, Khwies D, Ben-Meir A, Esh Broder E, Walfisch A, et al: Mild COVID-19 was not associated with impaired IVF outcomes or early pregnancy loss in IVF patients . J Clin Med 2022, 11 : 5265. Huri M, Noferi V, Renda I, Piazzini F, Benemei S, Coccia ME: The COVID-19 Pandemic Impact on the Outcome of Medically Assisted Reproduction Pregnancies . Front Reprod Health 2022, 4 : 860425. Albeitawi S, Al-Alami ZM, Hamadneh J, Alqam H, Qublan H, Al Natsheh M: COVID-19 infection and vaccine have no impact on in-vitro fertilization (IVF) outcome . Sci Rep 2022, 12 : 21702. Rageh KEA, Farag EA, Behery MA, Badreldin MA, Ali EA: The Impact of Previous Exposure to COVID-19 on the Outcome of ICSI Cycles . JBRA Assist Reprod 2023. Youngster M, Avraham S, Yaakov O, Rabbi ML, Gat I, Yerushalmi G, Baum M, Maman E, Hourvitz A, Kedem A: The impact of past COVID-19 infection on pregnancy rates in frozen embryo transfer cycles . J Assist Reprod Genet 2022, 39 : 1565–1570. ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine: The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators . Hum Reprod Open 2017, 2017 : hox011. Romanski PA, Aluko A, Bortoletto P, Elias R, Rosenwaks Z: Age-specific blastocyst conversion rates in embryo cryopreservation cycles . Reprod Biomed Online 2022, 45 : 432-439. Braga DP, Setti AS, Figueira RC, Machado RB, Iaconelli A, Jr., Borges EJ: Influence of oocyte dysmorphisms on blastocyst formation and quality . Fertil Steril 2013, 100 : 748–754. Piccolomini MM, Bonetti TC, Motta E, Serafini PC, Alegretti JR: How general semen quality influences the blastocyst formation rate: Analysis of 4205 IVF cycles . JBRA Assist Reprod 2018, 22 : 89-94. Loutradi KE, Tarlatzis BC, Goulis DG, Zepiridis L, Pagou T, Chatziioannou E, Grimbizis GF, Papadimas I, Bontis I: The effects of sperm quality on embryo development after intracytoplasmic sperm injection . J Assist Reprod Genet 2006, 23 : 69-74. Chen X, Shi H, Li C, Zhong W, Cui L, Zhang W, Geng L, Hu K, Fang M, Wei D, et al: The effect of SARS-CoV-2 infection on human embryo early development: a multicenter prospective cohort study . Sci China Life Sci 2023, 66 : 1697–1700. Wilkins J, Al-Inizi S: Premature ovarian insufficiency secondary to COVID-19 infection: An original case report . Int J Gynaecol Obstet 2021, 154 : 179-180. Luongo FP, Dragoni F, Boccuto A, Paccagnini E, Gentile M, Canosi T, Morgante G, Luddi A, Zazzi M, Vicenti I, Piomboni P: SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility . Cells 2022, 11. Colaco S, Chhabria K, Singh D, Bhide A, Singh N, Singh A, Husein A, Mishra A, Sharma R, Ashary N, Modi D: Expression map of entry receptors and infectivity factors for pan-coronaviruses in preimplantation and implantation stage human embryos . J Assist Reprod Genet 2021, 38 : 1709-1720. Montano M, Victor AR, Griffin DK, Duong T, Bolduc N, Farmer A, Garg V, Hadjantonakis AK, Coates A, Barnes FL, et al: SARS-CoV-2 can infect human embryos . Sci Rep 2022, 12 : 15451. Bhayana DP, Raja KA, Chitra J, Sonu B: Failure to Detect Viral Ribonucleic Acid in Follicular Fluid of a Severe Acute Respiratory Syndrome Coronavirus 2-Infected Female - A Report from the Indian Subcontinent . J Hum Reprod Sci 2022, 15 : 396-398. Barragan M, Guillén JJ, Martin-Palomino N, Rodriguez A, Vassena R: Undetectable viral RNA in oocytes from SARS-CoV-2 positive women . Hum Reprod 2021, 36 : 390-394. Burke CA, Skytte AB, Kasiri S, Howell D, Patel ZP, Trolice MP, Parekattil SJ, Michael SF, Paul LM: A cohort study of men infected with COVID-19 for presence of SARS-CoV-2 virus in their semen . J Assist Reprod Genet 2021, 38 : 785-789. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, et al: Evolution of antibody immunity to SARS-CoV-2 . Nature 2021, 591 : 639-644. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP: The trinity of COVID-19: immunity, inflammation and intervention . Nat Rev Immunol 2020, 20 : 363-374. Xie Y, Mirzaei M, Kahrizi MS, Shabestari AM, Riahi SM, Farsimadan M, Roviello G: SARS-CoV-2 effects on sperm parameters: a meta-analysis study . J Assist Reprod Genet 2022, 39 : 1555–1563. Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, Lee S, Wang C, Li H, Cheng L, Ai J: Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age . Reprod Biomed Online 2021, 42 : 260-267. Depuydt C, Bosmans E, Jonckheere J, Donders F, Ombelet W, Coppens A, Donders G: SARS-CoV-2 infection reduces quality of sperm parameters: prospective one year follow-up study in 93 patients . EBioMedicine 2023, 93 : 104640. Miller JE, Smith TT: The effect of intracytoplasmic sperm injection and semen parameters on blastocyst development in vitro . Hum Reprod 2001, 16 : 918-924. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, Yang X, Wang B, Chen L, Chen Q, et al: SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 . Nat Commun 2021, 12 : 1813. Han J, Zhang N, Chen D, Gong Y, Li G, Kong Y, Pu L, Chen C, Liu J, Wang Q, et al: Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity . Sci China Life Sci 2022, 65 : 223-226. Tables Table 1. Baseline characteristics of the women in the infected and uninfected groups before and after matching Before propensity score matching After propensity score matching Characteristic Uninfected group (n=2,660） Infected group (n=386) P value Uninfected group (n=698) Infected group (n=358) P value Age of the woman (y) 32 (29, 35) 33 (30, 35) 0.004 32 (30,35) 33 (30,35) 0.631 Infertility duration (y) 3 (1.5, 4) 3 (1.5, 4) 0.971 3 (1.5, 4.13） 3 (1.5, 4.0) 0.951 Primary infertility, n (%) 1359 (51.09%) 190 (49.22%) 0.493 350 (50.14%) 189 (52.79%) 0.415 Cycle number, n (%) 0.221 0.158 First cycle 2106 (79.17%) 316 (81.87%) 609 (87.25%) 301 (84.08%) Repeated cycles 554 (20.83) 70 (18.13%) 89 (12.75%) 57 (15.92%) AMH (ng/ml) 3.07 (1.70, 5.25) 3.24 (1.92, 5.21) 0.132 3.42 (1.87, 6.17) 3.23 (1.94, 5.17) 0.319 Basal FSH level (IU/L) 7.19 (5.94, 8.74) 7.21 (5.77, 8.67) 0.487 7.02 (5.87, 8.47) 7.10 (5.70, 8.64) 0.100 Body mass index (kg/m 2 ) 22.50 (20.43,25.16) 22.84 (20.99, 24.97) 0.177 22.65 (20.66, 25.23) 22.83 (20.99, 24.97) 0.610 Cause of infertility, n (%) 0.006 0.955 Tubal 997(37.48%) 143 (37.05%) 260 (37.25%) 138 (38.55%) Male factor 205(7.71%) 32 (8.29%) 54 (7.74%) 28 (7.82%) Anovulatory 285(10.71%) 33 (8.55%) 67 (9.60) 33 (9.22%) Unexplained 640(24.06%) 99 (25.65%) 197 (28.22%) 96 (26.82%) Diminished ovarian reserve 345(12.97%) 44 (11.40%) 79 (11.32%) 38 (10.61%) Endometriosis 162(6.09%) 22 (5.70%) 31 (4.44%) 21 (5.87%) Mixed factors 26(0.98%) 13 (3.37%) 10 (1.43%) 4 (1.12%) OS protocol, n (%) <0.001 0.809 GnRH-agonist 1153 (43.35%) 93 (24.09%) 175 (25.07%) 93 (25.98%) GnRH-antagonist 863 (32.44%) 226 (58.55%) 393 (56.30%) 204 (56.98%) CPOS 644 (24.21%) 67 (17.36%) 130 (18.62%) 61 (17.04%) Insemination method, n (%) 0.099 0.681 IVF 1828 (68.72%) 280 (72.54%) 499 (71.49%) 265 (74.02%) ICSI 709 (26.65%) 84 (21.76%) 153 (21.92%) 72 (20.11%) IVF+RICSI 123 (4.62%) 22 (5.70%) 46 (6.59%) 21 (5.87%) Gonadotropins dosage (IU) 2325 (1800, 2925) 2250 (1819, 2700) 0.061 2300 (1800, 2850) 2250 (1800, 2700) 0.415 Gn duration, d 9 (8, 11) 9 (8, 10) <0.001 9 (8, 10) 9 (8,10) 0.161 E2 on trigger day, pg/mL 2047(1188,3362) 1720(1108, 2731) <0.001 1726(973.2. 2976) 1752(1117, 2760) 0.864 Endometrial thickness 10(8,12) 10(8,12) 0.511 10(8,12) 10(8,12) 0.509 Note: Data are presented as the median (25th and 75th percentile) or number (%). Mann‒Whitney U statistics were used for continuous variables and chi-square tests were used for categorical variables. There were no significant differences after propensity score matching. AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2, Estradiol. Table 2. Embryo laboratory outcomes after matching Uninfected group (n=698) Infected group (n=358) P value 95% CI Average no. of oocytes retrieved 11 (6, 16) 11(6, 17) 0.646 -1.00-1.00） Mature oocyte rate, % 84.81 (71.43, 100) 82.35(69.23, 94.12) 0.138 -0.03-0.00 Normal fertilization rate, % 57.14 (40.00, 75.00) 56.25 (40.00, 71.43) 0.501 -0.04-0.02 Abnormal fertilization rate, % 0.00 (0.00, 12.50） 0.00 (0.00, 14.29) 0.840 0.00-0.00 Cleavage rate, % 100 (100, 100) 100 (100, 100) 0.659 0.00-0.00 High-quality embryo rate, % 37.50(11.46, 64.12) 44.44 (20.00, 66.67) 0.052 0.00-0.08 Blastocyst formation rate, % 73.33(50.00, 92.31） 66.67 (50.00, 87.50) 0.013 -0.08-0.00 Available blastocyst rate, % 62.50 (45.45, 80.00) 60.00 (40.00, 80.00) 0.438 --0.05-0.00 OR, Odds ratio; CI, confidence interval. Continuous variables are presented as the median (25th and 75th percentile), while categorical variables are presented as the % (n); P < 0.05 was considered statistically significant. Mature oocyte rate = Total number of mature oocytes/the total number of oocytes retrieved ×100%. 2PN fertilization rate =D1 number of 2PN oocyte/(total number of IVF fertilized oocytes + total number of MII oocytes injected) ×100%. D3 high-quality embryo rate =D3 high quality embryo number/normal fertilization cleavage embryo number ×100%. Blastocyst formation rate = the number of blastocysts formed/the number of Day 3 embryos for extended culture. Available blastocyst rate = the number of blastocysts available for cryopreservation/the number of Day 3 embryos available for extended culture. Table 3. Subgroup analysis based on the time interval from SARS-CoV-2 infection to oocyte retrieval Characteristic ≤30 d(n=69) 31~60 d (n=69) 61~90 d (n=119) ＞ 90 d (n=101) p value Age of the woman (y) 32(29, 34) 32(30, 36) 33(30, 35) 33(30, 35.5) 0.710 Infertility duration (y) 3.00(1.00, 3.50) 2.00(2.00, 4.00) 3.00(1.00, 5.00) 3.00(2.00, 5.00) 0.302 Primary infertility, n (%) 31(44.93) 34(49.28) 56(47.06) 56(55.45) 0.514 Cycle number, n (%) First cycle 59(85.51) 56(81.16) 101(84.87) 85(84.16) 0.896 Repeated cycles 10(14.50) 13(18.84) 18(15.13) 16(15.84) 0.896 AMH (ng/ml) 3.49(1.79, 6.11) 3.56(2.03, 4.97) 3.31(1.95, 5.36) 2.93(1.65, 4.73) 0.561 Basal FSH level (IU/L) 6.74(5.33, 8.91) 6.84(5.47, 8.41) 6.97(5.87, 8.60) 7.48(6.21, 8.75) 0.171 Body mass index (kg/m 2 ) 22.70(20.83, 24.35) 23.02(21.29, 24.83) 22.84(21.18, 25.62) 22.73(20.78, 24.97) 0.536 Cause of infertility, n(%) Tubal 31(44.93) 26(37.68) 39(32.77) 43(42.57) 0.251 Male factor 4(5.80) 3(4.35) 12(10.08) 9(8.91) 0.465 Anovulatory 8(11.59) 7(10.15) 13(10.92) 5(4.95) 0.369 Unexplained 15(21.74) 23(33.33) 28(23.53) 29(28.71) 0.355 Diminished ovarian reserve 8(11.59) 5(7.25) 15(12.61) 9(8.91) 0.635 Endometriosis 3(4.35) 5(7.25) 9(7.56) 5(4.95) 0.635 Mixed factors 0.000 0.000 3(2.52) 1(0.99) 0.460 OS protocol, n (%) ＜0.001 GnRH-agonist 23(33.33) 19(27.54) 24(20.17) 27(26.73) GnRH-antagonist 30(43.48) 32(46.38) 73(61.35) 69(68.32) CPOS 16(23.19) 18(26.09) 22(18.49) 5(4.95) Insemination method, n (%) 0.009 IVF 44(63.77) 42(60.87) 94(80.34) 83(83.00) ICSI 19(27.54) 20(28.99) 18(15.39) 14(14.00) IVF+RICSI 6(8.70) 7(10.15) 5(4.27) 3(3.00) Gonadotropins dosage (IU) 2175(1750,2888) 2325(1950,2663) 2175(1800,2700) 2250(1813,2700) 0.628 Gn duration, d 9(8,10) 9(8,10) 9(8,10) 9(8,10) 0.576 E2 on trigger day (pg/mL) 2037(1310,3281) 1860(1179,2705) 1681(1087,2570) 1622(984.9,2683) 0.075 Average no. of oocytes retrieved 10.00(6.00, 16.50) 10.00(6.00, 17.50) 12.00(6.00, 17.00) 11.00(6.00, 17.00) 0.986 Mature oocyte rate, % 0.81(0.70, 0.91） 0.83(0.67, 0.95) 0.83(.72, 0.95) 0.82(0.67,1.00) 0.814 Normal fertilization rate, % 0.53(0.37,0.70) 0.58(0.38, 0.73) 0.60(0.46, 0.72) 0.54(0.39, 0.75) 0.278 Abnormal fertilization rate, % 0(0, 15.04) 0(0, 12.50) 5.13(0, 13.33) 5.28(0, 15.38) 0.331 Cleavage rate, % 100(100, 100) 100(100, 100) 100(100, 100) 100(100, 100) 0.654 High-quality embryo rate, % 50.00(33.33, 65.91) 33.33(0, 53.33) 50.00(29.64, 66.67) 45.56(15.42, 66.67) 0.011 Blastocyst formation rate, % 73.68(50.00, 100) 50.00(31.67, 83.33) 69.23(55.56, 87.50) 66.67(50.00, 83.33) 0.012 Available blastocyst rate, % 66.67(50.00, 89,44) 50.00(20.00, 71.71) 66.67(50.00, 81.82) 60.00(40.00, 72.32) 0.003 High-quality blastocyst rate, % 0(0, 28.57) 0(0, 29.67) 20.00(0, 40.00) 3.57(0, 42.14) 0.109 Implantation rate, % 56.94（41/72） 57.63（34/59） 56.44（57/101） 48.24（41/85） 0.593 Biochemical pregnancy rate, % 70.97（44/62） 75.93（41/54） 67.35（66/98） 64.47（49/76） 0.537 Clinical pregnancy rate, % 61.29（38/62） 62.96（34/54） 58.16（57/98） 53.95（41/76） 0.730 Early pregnancy loss rate, % 13.16（5/38） 5.88（2/34） 15.79（9/57） 7.32（3/41） 0.430 Note: Data are presented as the median (25th and 75th percentile) or number (%). Mann‒Whitney U statistics were used for continuous variables and chi-square tests were used for categorical variables. AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2, Estradiol. Table 4. Linear regression analysis of the variables for the blastocyst formation rate based on the SARS-CoV-2 infection interval AMH, anti-Müllerian hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2. Table 5. Clinical outcomes after the first cycle of embryo transfer after matching Uninfected group (n=698) Infected group (n=358) Z value p value OR (95% CI) Single embryo transfer rate, % 85.67 (520/607) 88.62(257/290) 1.215 0.224 0.76(0.50-1.17) Embryo transfer strategies, n(%) 0.4026 0.687 0.94(0.70-1.26) Fresh embryo transfer 199 (32.78) 99 (34.14) Frozen embryo transfer 408 (67.22) 191 (65.86) Implantation rate, % 54.32 (377/694) 53.87 (174/323) 0.1349 0.893 1.02(0.78-1.33) Biochemical pregnancy rate, % 65.57 (398/607) 68.62 (199/290) 0.906 0.365 0.87(0.65-1.17) Clinical pregnancy rate, % 57.00 (346/607) 58.62 (170/290) 0.4588 0.646 0.94(0.70-1.24) Early pregnancy loss rate, % 10.98 (38/346) 10.59 (18/170) 0.1354 0.892 1.04(0.57-1.94) Ectopic pregnancy rate, % 1.15 (4/346) 0 / 0.307 0.00(0.00-2.04) No available embryo cycle rate 9.60 (67/698) 8.04 (32/398) 0.8657 0.387 1.21(0.79-1.88) Additional Declarations No competing interests reported. Supplementary Files Supplementaryfile1.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3172915","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":219367097,"identity":"11c96201-b4fc-47bb-9af2-e2bd818286a8","order_by":0,"name":"Yanhui Li","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yanhui","middleName":"","lastName":"Li","suffix":""},{"id":219367098,"identity":"0c86eed4-bc1f-4c56-ae88-bf4d0dd7562b","order_by":1,"name":"Xiaofang Ding","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xiaofang","middleName":"","lastName":"Ding","suffix":""},{"id":219367099,"identity":"22af2243-9877-4912-8848-fb4fb8d6f606","order_by":2,"name":"Dan Luo","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Dan","middleName":"","lastName":"Luo","suffix":""},{"id":219367100,"identity":"1cc25c3b-c45c-4975-9d81-ef749ea35117","order_by":3,"name":"Tao Li","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Tao","middleName":"","lastName":"Li","suffix":""},{"id":219367101,"identity":"0a76d490-b5c8-42f3-bd36-795a4b189ac6","order_by":4,"name":"Lin Liu","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lin","middleName":"","lastName":"Liu","suffix":""},{"id":219367102,"identity":"947f5e03-9bfc-4061-b521-19fe78e665aa","order_by":5,"name":"Bingjie Li","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Bingjie","middleName":"","lastName":"Li","suffix":""},{"id":219367103,"identity":"dfeee1cc-a260-43e9-b27e-81de568957c9","order_by":6,"name":"Chunyan Chen","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Chunyan","middleName":"","lastName":"Chen","suffix":""},{"id":219367104,"identity":"e2c3bbb7-8e3c-43ed-871e-4715285712b4","order_by":7,"name":"Yi Liu","email":"","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Liu","suffix":""},{"id":219367105,"identity":"a968df00-81c7-406e-b732-64c9bf210e76","order_by":8,"name":"Hui Ding","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAyUlEQVRIiWNgGAWjYBACxvaGxAcJPDY8/OwNRGph7jnw2OCDTJqcZM8BIrWwz0h8JjnD5rCxwY0EIrXwzkhONubJSUtsuPl44w2GGptogloke54lPuY5Y5PYODut2ILhWFpuAyEthu05yca8PWmJzdI5ZhKMDYcJa7E/kP9Nmvff4cQ2yTNEamHsSEiTnMFz2JhHgodYLT0Hkg0+8KTJSfAA/ZJAjF/gUWl//PDGGx9qbAhrQQYGEgmkKIdoIVXHKBgFo2AUjAwAAELQRCk2aR2bAAAAAElFTkSuQmCC","orcid":"","institution":"Union Hospital, Huazhong University of Science and Technology","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Hui","middleName":"","lastName":"Ding","suffix":""}],"badges":[],"createdAt":"2023-07-15 10:59:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3172915/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3172915/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":40397734,"identity":"6d19577b-7a09-42d0-99ed-12b749d63e88","added_by":"auto","created_at":"2023-07-21 19:48:56","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":146514,"visible":true,"origin":"","legend":"\u003cp\u003eStudy flow chart\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-3172915/v1/becf10d50c02cd1f47933534.png"},{"id":40397735,"identity":"033a5b50-4c4d-4f54-ac27-38a64b4f96b3","added_by":"auto","created_at":"2023-07-21 19:48:56","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":205613,"visible":true,"origin":"","legend":"\u003cp\u003ePropensity score matching between the infected group and the uninfected group\u003c/p\u003e\n\u003cp\u003ea-b. The distribution of propensity scores before and after matching\u003c/p\u003e\n\u003cp\u003ec-d. The distribution of standard differences before and after matching\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-3172915/v1/06fe28d514fbfbbc9c221208.png"},{"id":40430049,"identity":"b40cee41-43a6-46b9-9082-7590a5b2c3e4","added_by":"auto","created_at":"2023-07-23 09:59:36","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":949816,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3172915/v1/4941b076-f5a0-40c6-893d-037ebca96303.pdf"},{"id":40397733,"identity":"7f5f6a2b-0060-40ac-8eeb-aeb2502fc51f","added_by":"auto","created_at":"2023-07-21 19:48:56","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":24459,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementaryfile1.docx","url":"https://assets-eu.researchsquare.com/files/rs-3172915/v1/b91b4111126d7f9fcd8ec73b.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Effect of SARS-CoV-2 infection on IVF/ICSI-ET outcomes: A propensity score-matched cohort study","fulltext":[{"header":"Background","content":"\u003cp\u003eThe World Health Organization (WHO) declared that COVID-19 was no longer a public health emergency of international concern (PHEIC) on May 5, 2023. SARS-CoV-2 is still evolving [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], resulting in new cases and reinfections in the population [\u003cspan additionalcitationids=\"CR3\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. As SARS-CoV-2 is a new virus, we still need to improve our understanding of it, especially its effects on human reproduction and assisted reproductive technology (ART) [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] Currently, it is believed that the SARS-CoV-2 virus damages cells or tissues by infecting and replicating in cells, which requires the expression of SARS-CoV-2 receptors, such as angiotensin converting enzyme 2 (ACE2), basigin (BSG), transmembrane serine protease 2 (TMPRSS2) and cathepsin L (CTSL) [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. It is noteworthy that all the aforementioned viral receptor mRNAs are expressed in most of the human female reproductive tract, including the ovaries (including follicular granulosa cells) [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] and endometrium [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. A few studies have also shown that ACE2, BSG, and/or TMPRSS2 genes and proteins are expressed in human oocytes, fertilized eggs, and blastocysts [\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Therefore, the effects of SARS-CoV-2 infection on the pregnancy outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) have been the focus of attention for ART staff and patients.\u003c/p\u003e \u003cp\u003eA retrospective study from Israel showed that IVF treatment within one year after SARS-CoV-2 infection did not affect the pregnancy outcomes after fresh embryo transfer. It should be noted that this study did not mention whether or not the control group was thoroughly screened for SARS-CoV-2 infection. [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. However, several studies have found that the rate of high-quality embryos [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] and retrieved oocytes [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] was decreased in patients who underwent IVF treatment after being infected with SARS-CoV-2. Another study discovered that when only the male partner was infected with SARS-CoV-2, the blastocyst formation rate was reduced, even though the IVF procedure was performed more than 4 months after SARS-CoV-2 infection [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. It should be noted that all of these studies had small sample sizes and did not conduct stratified analyses of the time from SARS-CoV-2 infection to oocyte retrieval. As a result, the impact of SARS-CoV-2 infection on IVF treatment outcomes remains unclear. The clinical and laboratory results of patients who underwent IVF treatment during the acute infection period, in particular, were mostly from case reports [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDue to China's effective and strict epidemic prevention and control policy, ART services in mainland China were carried out in a nonepidemic state from the beginning of 2020 to November 2022. However, with the attenuated pathogenicity of the omicron subvariants and increasing vaccination coverage, the dynamic zero-COVID policy was terminated in mainland China on December 7, 2022 [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. A wave of SARS-CoV-2 infections was reported in mainland China from December 2022 to January 2023 [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. This infection wave was mainly caused by the SARS-CoV‐2 omicron variants BF.7 and BA.5.2 [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. During this time, our center also treated more SARS-CoV-2-infected couples, providing a good observation sample. Thus, in the present study, we collected IVF data from SARS-CoV-2-infected couples who underwent IVF treatment from December 7, 2022, to March 7, 2023, in our center to evaluate the effects of SARS-CoV-2 infection on embryo development and IVF clinical outcomes.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e\u003cb\u003eStudy population and design\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eIn this retrospective cohort study, all couples who underwent their first or second cycle of IVF or ICSI treatment at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from December 7, 2022, to March 7, 2023, were enrolled. Couples in which both partners were infected with SARS-CoV-2 on or before the trigger day (based on PCR tests for detecting SARS-CoV-2 RNA from nasopharyngeal swabs) and the female partner was aged between 21 and 50 years were included as the SARS-CoV-2-positive group. To avoid the possibility of unknown and asymptomatic incubation periods, the current study also enrolled all couples who underwent their first or second cycle of IVF or ICSI treatment in our center from June 1, 2021, to November 30, 2022 (during which the dynamic zero-COVID policy was implemented in mainland China). Couples with no history of SARS-CoV-2 infection and in which the female partner was aged 21\u0026ndash;50 years were included as the SARS-CoV-2-negative (control) group. Couples in both groups underwent at least two PCR tests to detect SARS-CoV-2 RNA during controlled ovarian stimulation (COS), namely, before COS and on the trigger day. Pulmonary computed tomography was also performed to rule out lung lesions. Moreover, a careful medical history was taken and a COVID-19 questionnaire survey was performed for all patients before the initiation of COS. The following patients were excluded: (a) patients who were missing important information; (b) patients who were lost to follow-up; (c) patients who used donor eggs or sperm; (d) patients who underwent total or partial oocyte freezing; and (e) patients who underwent preimplantation genetic testing cycles. Propensity score matching between the infected group and the uninfected group was performed at a ratio of 1:2 to create groups that had comparable characteristics. The present study was approved by the Ethical Committee of Union Hospital (no. 2023-S0462), and individual consent for this retrospective analysis was waived.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eOvarian stimulation\u003c/h2\u003e \u003cp\u003eIn this study, most patients underwent the gonadotropin-releasing hormone (GnRH) agonist protocol or the GnRH antagonist protocol. A few patients underwent the clomiphene-primed ovarian stimulation (CPOS) luteal phase stimulation protocol. For the GnRH agonist protocol, tripreilin acetate was injected at 0.05 mg/d (Ferring Pharmaceuticals, German) at the middle luteal stage of the previous cycle for pituitary downregulation. When the downregulation standard was reached (serum luteinizing hormone level\u0026thinsp;\u0026lt;\u0026thinsp;5 IU/L, serum estradiol level\u0026thinsp;\u0026lt;\u0026thinsp;50 pg/ml, endometrial thickness\u0026thinsp;\u0026lt;\u0026thinsp;10 mm, no functional ovarian cysts), urine follicle-stimulating hormone (uFSH) (Zhuhai Lizon Pharmaceutical, China) or recombinant follicle-stimulating hormone (rFSH) (Merck Serono, Switzerland) was initiated with at 150\u0026ndash;225 U. Adjustments were made according to the ovarian response. For the GnRH antagonist protocol, ovarian stimulation was initiated with 150\u0026ndash;225 IU uFSH or rFSH daily. The GnRH antagonist (0.25 mg, Cetrotide, 0.25 mg SC; Merck-Serono) was administered daily to prevent premature ovulation if at least one of the following criteria was met: at least one follicle measured\u0026thinsp;\u0026gt;\u0026thinsp;14 mm; an E2 serum level\u0026thinsp;\u0026gt;\u0026thinsp;500 pg/mL; or an LH serum level\u0026thinsp;\u0026gt;\u0026thinsp;10 IU/L. When bilateral ovaries had\u0026thinsp;\u0026ge;\u0026thinsp;2\u0026thinsp;~\u0026thinsp;3 follicles with diameters\u0026thinsp;\u0026gt;\u0026thinsp;18 mm, 10000 IU human chorionic gonadotropin (hCG) (Lizhu Pharmaceutical Trading Co., People\u0026rsquo;s Republic of China) or 250 mg Ovidrel (Merck Serono S.p.A., Modugno, Italy) was administered to trigger the final maturation of the oocytes. Transvaginal oocyte retrieval was performed under ultrasound guidance 34\u0026ndash;36 h after hCG administration.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eFertilization and embryo evaluation\u003c/h2\u003e \u003cp\u003eFertilization was achieved by IVF or ICSI according to the male partner\u0026rsquo;s sperm quality. For IVF fertilization, approximately 20,000 motile sperm were added to each oocyte. If the total number of motile sperm was \u0026lt;\u0026thinsp;5\u0026times;106/ml or the proportion of normal sperm was \u0026lt;\u0026thinsp;1%, ICSI was performed. The presentation of 2 pronuclei (2PN) 16\u0026ndash;18 h after insemination was regarded as normal fertilization. After 72 h of in vitro culture, embryos were evaluated according to the evenness of blastomeres and the percentage of embryo fragmentation [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Embryos comprising 6\u0026ndash;8 cells and those of grade 1 or 2 were regarded as top-quality embryos. Some of the embryos were cultured into blastocysts for an additional 2\u0026ndash;4 days. Blastocysts were evaluated using Gardner's grading scale [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e] Throughout the study period, the staff at the center, as well as the culture conditions and culture medium in the embryo laboratory, remained unchanged.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eFresh and frozen embryo transfer\u003c/h2\u003e \u003cp\u003eEmbryo transfer was performed under abdominal ultrasound guidance, with a maximum of 2 cleavage-stage embryos or blastocysts transferred each time. The \u0026ldquo;freeze-all\u0026rdquo; strategy was employed for couples in the acute stage of SARS-CoV-2 infection. If the couples met the criteria for fresh embryo transfer, embryo transfer was performed on Day 3, 5 or 6 after oocyte retrieval. The surplus embryos were further cultured in G2-plus medium (Vitrolife, Gothenburg, Sweden) up to Day 5\u0026ndash;6 until they reached the blastocyst stage, and the available blastocysts were frozen by vitrification. For frozen embryo transfer, most of the enrolled patients underwent hormone replacement cycles to prepare the endometrium. The details of the vitrification procedure and endometrial preparation were described previously [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eSARS-CoV-2 nucleic acid tests\u003c/h2\u003e \u003cp\u003eReal-time polymerase chain reaction (RT‒PCR) (Mingde Biotechnology Co., Ltd, Wuhan, China) was carried out to detect the presence of SARS-CoV-2 RNA in the specimens collected from nasopharyngeal swabs. The open reading frame 1ab (ORF1ab) and N genes of SARS-CoV-2 were the target genes for RT\u0026ndash;PCR. A cycle threshold (Ct) of less than 37 denoted positive SARS-CoV-2 findings.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eOutcome measures\u003c/h2\u003e \u003cp\u003eThe important quality control indices during COS and in vitro embryo culture and pregnancy outcomes in the first trimester were analyzed and compared between the two groups. The primary outcome measure was the clinical pregnancy rate after the first embryo transfer cycle. The secondary outcome measures included the number of oocytes retrieved, the number of mature oocytes, the number of normal fertilizations, the blastocyst formation rate, the number of available embryos, early pregnancy loss, etc. The above measures were calculated according to our previous report [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The high-quality embryo rate was defined as the number of high-quality embryos on Day 3 divided by the number of normally fertilized cleavage embryos. The blastocyst formation rate was defined as the number of blastocysts formed divided by the number of normally fertilized oocytes. The available blastocyst rate was defined as the number of blastocysts for cryopreservation and transfer divided by the number of normally fertilized oocytes. A clinical pregnancy was defined as the identification of a gestational sac 4 weeks after embryo transfer. A biochemical pregnancy was defined as serum β-hCG level\u0026thinsp;\u0026gt;\u0026thinsp;5 mU/mL. The denominator of the clinical pregnancy rate and biochemical pregnancy rate was the number of embryo transfer cycles.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analyses\u003c/h2\u003e \u003cp\u003eKolmogorov\u0026ndash;Smirnov or Shapiro\u0026ndash;Wilk normality tests were used for all continuous variables. Variables with a normal distribution are presented as \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\stackrel{-}{x}\\pm s\\)\u003c/span\u003e\u003c/span\u003e. Statistical comparison was performed by Student\u0026rsquo;s \u003cem\u003et\u003c/em\u003e test. Variables that did not conform to a normal distribution are given as the median\u0026thinsp;+\u0026thinsp;interquartile range (IQR), and differences between groups were compared by the Mann‒Whitney U test. Categorical variables are presented as the n (%), and statistical comparisons were performed using the chi-square test.\u003c/p\u003e \u003cp\u003eStandard propensity score matching was conducted using nearest neighbor matching with a caliper of 0.02. The following baseline characteristics were matched without replacement at a ratio of 1:2: female age (years), female body mass index (BMI, kg/m2), basal follicle stimulating hormone level (FSH, mIU/mL), basal anti-M\u0026uuml;llerian hormone level (AMH, ng/mL), infertility type (primary or secondary), infertility duration (years), infertility cause, insemination method (IVF or ICSI), and COS protocol (GnRH agonist protocol, GnRH antagonist protocol, and other protocols). Women who were not matched were excluded from the analyses. Two-tailed P values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were considered statistically significant. The Statistical Package for Social Sciences software (SPSS Inc., Version 24.0, Chicago) and R version 4.1.0 (R Core Team, Vienna, Austria) were used for data analyses.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eAmong those who underwent IVF/ICSI at our center between December 7, 2022 and March 7, 2023, a total of 386 couples met the above inclusion and exclusion criteria,\u0026nbsp;and both partners\u0026nbsp;were\u0026nbsp;infected with SARS-CoV-2 on or before the trigger day. A total of 2660 uninfected patients who underwent IVF/ICSI between June 1, 2021 and November 30, 2022,\u0026nbsp;and met the exclusion and inclusion criteria were selected as controls. After propensity score matching was performed, 358 patients were included in the infected group,\u0026nbsp;and 698 patients were included in the uninfected group (Figure. 1). The baseline demographic characteristics of the couples after matching are presented in Table 1. No significant differences were found with regard to any baseline characteristics between the 2 groups (P\u0026gt;0.05). The distribution of propensity scores and standard differences before and after matching between the groups are presented in Figure. 2. The overlap in density represented the balance of the distribution between the two groups, which indicated that the patients were well matched after propensity score matching.\u003c/p\u003e\n\u003cp\u003eThe clinical manifestations of the 358 matched female partners after infection with SARS-CoV-2\u0026nbsp;are\u0026nbsp;presented in Supplementary Table 1.\u0026nbsp;A total of\u0026nbsp;80.17% of the women (287 women) had mild COVID-19, with fever, headache, muscle aches, sore throat, and other symptoms but no lung imaging changes\u0026nbsp;[25].\u0026nbsp;A total of\u0026nbsp;9.5% of the women (34 women) had moderate COVID-19, and they had typical lung imaging changes in addition to the clinical symptoms described above.\u0026nbsp;A total of\u0026nbsp;10.33% of the women (37 women) were asymptomatic and were diagnosed by SARS-CoV-2 mRNA screening during IVF treatment. None of the patients were diagnosed\u0026nbsp;with\u0026nbsp;severe\u0026nbsp;disease\u0026nbsp;[26].\u003c/p\u003e\n\u003cp\u003eFor the oocyte and embryo outcomes, there were no significant differences between the two groups in the average number of oocytes retrieved, the mature oocyte rates, the normal fertilization rates, the abnormal fertilization rates, and the cleavage rates. However, compared with the\u0026nbsp;uninfected\u0026nbsp;(control) group, the blastocyst formation rate in the infected group was significantly decreased [73.33% (IQR 50.00%-92.31%) vs. 66.67% (IQR 50.00%-87.5%); p\u0026lt;0.05], and the high-quality embryo rate on Day 3 also showed a downward trend (Table 2).\u0026nbsp;This\u0026nbsp;indicates that embryo developmental potential may be affected in SARS-CoV-2 patients. The infected group was stratified into subgroups by the interval from SARS-CoV-2 infection to oocyte retrieval (30\u0026nbsp;days, 31-60 days, 61-90 days, and \u0026gt;\u0026nbsp;90\u0026nbsp;days). Subgroup analysis revealed that couples who underwent IVF 31-60 days\u0026nbsp;after SARS-CoV-2 infection had significantly lower rates of high-quality\u0026nbsp;embryos\u0026nbsp;on Day 3, blastocyst formation and available blastocysts than the other three subgroups and the uninfected control group. However, blastocyst formation was not significantly affected in patients who underwent IVF within 30 days or more than 60 days after SARS-CoV-2 infection (Table 3).\u003c/p\u003e\n\u003cp\u003eTo exclude possible confounding factors of the blastocyst formation rate, we further conducted a linear-regression analysis including patient age, body mass index, ovarian stimulation protocol, fertilization method, type of infertility, cause of infertility, number of mature oocytes, and D3 high-quality embryo rate. The results also suggested that SARS-CoV-2 infection, together with female age and the D3 high-quality embryo rate, was a significant predictor of the blastocyst formation rate (Supplementary Table 2). More notably, the linear regression analysis model for blastocyst formation rate stratified by the time from SARS-CoV-2 infection to oocyte retrieval further strengthened the univariate results, with 31-60 days after SARS-CoV-2 infection remaining a significant variable (p\u0026lt;0.001, 95% CI\u0026nbsp;-0.211 - -0.074). On the other hand, IVF within 30 days or more than 60 days following SARS-CoV-2 infection was not a significant predictor of the blastocyst formation rate (Table 4).\u003c/p\u003e\n\u003cp\u003eFor clinical pregnancy outcomes, 290 couples in the infected group (99 couples underwent fresh embryo transfer) and 607 couples in the matched uninfected group (139 couples underwent fresh embryo transfer) completed the first cycle of embryo transfer. There was no significant difference in embryo implantation rate (54.88% vs. 49.54%), biochemical pregnancy rate (68.62% vs. 65.56%), clinical pregnancy rate (58.62% vs. 57.01%), or early abortion rate (10.59% vs. 10.98%) after the first cycle of embryo transfer between the two groups (Table 5).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn the current study, we enrolled SARS-CoV-2-infected couples who underwent IVF treatment during the first three months after the public health control measures were adjusted in mainland China; these infected couples were matched to uninfected couples who underwent IVF treatment during the period of the dynamic zero-COVID-19 policy in mainland China. IVF treatment outcomes were compared between the two groups, and the results showed that the blastocyst formation and available blastocyst rates were significantly decreased in couples who underwent IVF treatment 31\u0026ndash;60 days after SARS-CoV-2 infection, implying that we should remain concerned about the potential adverse effects of SARS-CoV-2 on embryo development.\u003c/p\u003e \u003cp\u003eSeveral pathogens, such as hepatitis virus, human immunodeficiency virus, and Zika virus [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e], may have variable impacts on the physiopathology of the reproductive organs, leading to infertility or poor ART outcomes [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. Therefore, when the new SARS-CoV-2 virus emerged and spread globally, researchers focused on the impact of infection with this virus on human reproduction and ART outcomes [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The effects of SARS-CoV-2 infection on the laboratory and clinical outcomes of ART have not yet been consistently documented in the literature [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan additionalcitationids=\"CR30\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. An unclear infection status, the inability to correctly measure the time between SARS-CoV-2 infection and ART treatment, and the absence of a stratification analysis on the time of oocyte retrieval relative to SARS-CoV-2 infection could all be contributing factors. For instance, the pregnancy outcomes of patients who underwent IVF treatment before and during the COVID-19 pandemic were compared in the retrospective studies of Huri et al. [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] and Rageh et al. [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e], but the authors failed to clarify whether the cohorts who underwent IVF treatment during the COVID-19 pandemic were infected with SARS-CoV-2. The largest retrospective analysis of IVF outcomes in SARS-CoV-2 patients to date was reported in a 2022 report from Israel [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. By comparing the IVF data of 121 patients previously infected with COVID-19 and 121 uninfected patients, the researchers discovered that IVF treatment within one year after SARS-CoV-2 infection had no effect on the outcomes of fresh embryo transfer. Nonetheless, it should be highlighted that it was not made clear in this study whether the control group underwent rigorous testing for SARS-CoV-2 infection [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Furthermore, in another study, the same group reported that patients with previous SARS-CoV-2 infection who underwent frozen embryo transfer cycles with oocytes retrieved prior to infection had lower pregnancy rates, notably those who had recovered fewer than 60 days before embryo transfer [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. More importantly, the clinical outcomes of patients who underwent IVF during the acute period of SARS-CoV-2 infection are mostly described in case reports [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. As a result, more research on the laboratory and clinical outcomes of ART in patients during and after SARS-CoV-2 infection is needed.\u003c/p\u003e \u003cp\u003e In the current study, we performed propensity score matching to eliminate the imbalance of the number and distribution of participants between groups. Thus, our findings are much more convincing and reliable. Notably, in the current study, the blastocyst formation rates were significantly lower in couples who underwent IVF treatment 31\u0026ndash;60 days after SARS-CoV-2 infection than in uninfected couples [50% (31.67%, 0.83.33%) vs. 73.33% (50.00%, 92.31%)] and were also significantly lower than the benchmark value recommended by the Vienna consensus, which suggests that the blastocyst formation rate should be above 60% [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. The rate of blastocyst formation is an essential key performance indicator (KPI) in embryo laboratories. This KPI is influenced not only by the whole culture system [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] but also by female age [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e], oocyte quality [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e] and male sperm quality [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. We thoroughly checked the post of embryo laboratory staff and the culture medium used for embryo culture and discovered that the above conditions were constant over the study period. Furthermore, there was no difference in the age of female partners across subgroups and the uninfected group. As a result, we assumed that the lower rate of blastocyst formation in the subgroup who underwent IVF treatment 31\u0026ndash;60 days after SARS-CoV-2 infection was due to SARS-CoV-2 infection. Further linear retrospective analysis in our current study supported this conclusion. The negative effects of SARS-CoV-2 infection on embryo developmental potential have already been reported in several small-sample retrospective studies. An observational study reported that the proportion of high-quality embryos in patients decreased after SARS-CoV-2 infection, according to a self-controlled analysis of 9 patients [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Another study found that couples undergoing IVF treatment in which only the male partner was infected with the SARS-CoV-2 virus also had lower blastocyst formation rates [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. However, a recent prospective cohort study by Chen et al. [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e] included 706 couples who underwent IVF treatment between December 1, 2022, and January 11, 2023, when China's epidemic control policy was initially relaxed. Surprisingly, they reported that the infected patients had more normally fertilized oocytes than the noninfected patients, but no significant differences were observed between the two groups in oocyte outcomes, such as the number of oocytes retrieved, oocyte maturation rate and normal fertilization rate (these observations were similar to the results obtained in the current study). It is crucial to note, however, that the time of oocyte retrieval relative to the time of SARS-CoV-2 infection was less than 2 weeks in most patients in their study, and they also did not disclose the blastocyst formation rates or clinical pregnancy outcomes of the infected women.\u003c/p\u003e \u003cp\u003eThe SARS-CoV-2 host receptors ACE2 and TMPRSS2 have been found in ovarian tissues [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e], oocyte cumulus complexes [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e], oocytes [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e], and blastocysts [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. An in vitro study further revealed that fluorescent reporter virions pseudotyped with SARS-CoV-2 Spike (S) glycoprotein can infect trophectoderm cells. However, SARS-CoV-2 mRNA has yet to be found in infected patients' follicular fluid [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e], granular cells [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e], oocytes [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e], or semen [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. Therefore, we believe that the decrease in the blastocyst formation rate in couples 31\u0026ndash;60 days after SARS-CoV-2 infection observed in the current study was more likely due to indirect effects of SARS-CoV-2 infection. The decreased blastocyst formation rate may be attributed to several potential causes. First, the SARS-CoV-2 virus can induce an upregulation of proinflammatory cytokines and systemic oxidative stress in infected individuals [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e], which may damage the human gonads. It has been reported that the menstrual cycles of women and semen parameters of men significantly changed approximately 2 months after SARS-CoV-2 infection [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Approximately 30 days after SARS-CoV-2 infection, these damaging effects on the gonads reach their peak [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. Studies have shown that sperm progressive motility and morphology are closely connected with the blastocyst formation rate [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. In the current study, we also found a significant increase in the proportion of early rescue ICSI in the 31\u0026ndash;60 days post-SARS-CoV-2 infection.. Second, during SARS-CoV-2 infection, the body develops neutralizing antibodies, which peak 3\u0026ndash;4 weeks after infection [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. A previous study showed that anti-SARS-CoV-2 IgG antibodies can be detected in follicular fluid; in an in vitro experiment, the expression of steroidal acute regulatory protein (StAR), estrogen receptor β (Erβ) and vascular endothelial growth factor (VEGF) in granulosa cells was significantly reduced after the stimulation of follicular fluid from recovered COVID-19 patients. It is suggested that SARS-CoV-2 infection affects the follicular microenvironment and may have adverse effects on female reproductive outcomes. Although the clinical outcomes of first-cycle embryo transfer in couples who underwent IVF treatment within 31\u0026ndash;60 days of SARS-CoV-2 infection were unaffected, it remains to be seen whether the decreased blastocyst formation rate in these patients will have an effect on the cumulative live birth rate. Furthermore, long-term follow-up is required to clarify the offspring safety of IVF treatment at different times following SARS-CoV-2 infection.\u003c/p\u003e \u003cp\u003eThere are some limitations in this study. First, it was a retrospective study, so various confounding factors are likely to affect the study results. The PSM approach was used in the current study, and patients were matched for 9 basic characteristics at a ratio of 1:2 to exclude the influence of confounding factors as much as possible. However, some known or unknown confounding factors may still affect the statistical results. Second, to rule out the possibility of unknown and asymptomatic incubation periods, the current study included patients undergoing IVF treatment at different times as controls, resulting in the proportion of patients completing the first embryo transfer being different between the two groups, which may have an impact on the comparison of the clinical outcomes of the patients in the two groups. Third, due to the short follow-up period in the current study, data on the live birth rate of SARS-CoV-2-infected and uninfected patients undergoing IVF were lacking. In the future, we will continue to follow up with our study cohort to determine the impact of SARS-CoV-2 infection on the cumulative live birth rate. Finally, there were no severe COVID-19 patients included in this study, which means that the results may not accurately represent the overall impact of SARS-CoV-2 infection on IVF treatment.\u003c/p\u003e \u003cp\u003eIn conclusion, the results of the current study showed that SARS-CoV-2 infection had no effect on the clinical pregnancy outcomes after the first embryo transfer cycle, but the couples who underwent IVF treatment 31\u0026ndash;60 after SARS-CoV-2 infection had significantly lower blastocyst formation and blastocyst availability rates. Prospective studies are still needed to confirm these findings. However, until more definitive evidence is available, it is appropriate to postpone IVF beyond 2 months, if possible, in couples with SARS-CoV-2 infection.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eART: assisted reproductive technology; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; COVID-19: coronavirus disease 2019; IVF: in vitro fertilization; PSM: propensity-score matched; WHO: World Health Organization; PHEIC: public health emergency of international concern; ACE2: angiotensin converting enzyme 2; BSG: basigin (BSG); TMPRSS2: transmembrane serine protease 2; \u0026nbsp;CTSL: cathepsin L; IVF/ICSI: in vitro fertilization/intracytoplasmic sperm injection; COS: controlled ovarian stimulation; GnRH: gonadotropin-releasing hormone; CPOS: clomiphene-primed ovarian stimulation; uFSH: urine follicle-stimulating hormone; rFSH: recombinant follicle-stimulating hormone; hCG: human chorionic gonadotropin; RT-PCR: Real-time polymerase chain reaction; IQR: interquartile range; BMI: body mass index; AMH: anti-M\u0026uuml;llerian hormone; KPI: key performance indicator.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis retrospective study was approved by\u0026nbsp;the Medical Ethical Committee of Union\u0026nbsp;Hospital\u0026nbsp;(no. 2023-S0462), and individual consent for this retrospective analysis was waived.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by Hubei Provincial Natural Science Foundation of China (No. 2022CFB243).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eYL and HD conceived and designed the study. YL and HD contributed to acquisition of the data. YL and HD contributed to the analysis. YL, HD, YL, TL and BL contributed to the interpretation of the data. All authors made contributions to drafting and revising the article critically for important intellectual content. All authors approved the final version of the article to be published.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to express our gratitude to Dr. Zhenyuan Chen for his statistical advice. We also would like to thank our colleagues at the Reproductive Medicine Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMarkov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A: The evolution of SARS-CoV-2\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eNat Rev Microbiol \u003c/em\u003e2023, 21\u003cstrong\u003e:\u003c/strong\u003e361-379.\u003c/li\u003e\n\u003cli\u003eAltarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, Coyle P, Yassine HM, Al-Khatib HA, Benslimane FM, et al: Protection against the Omicron Variant from Previous SARS-CoV-2 Infection\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eN Engl J Med \u003c/em\u003e2022, 386\u003cstrong\u003e:\u003c/strong\u003e1288-1290.\u003c/li\u003e\n\u003cli\u003eVicentini M, Venturelli F, Mancuso P, Bisaccia E, Zerbini A, Massari M, Cossarizza A, De Biasi S, Pezzotti P, Bedeschi E, et al: Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eEur Surveill \u003c/em\u003e2023, 28\u003cstrong\u003e:\u003c/strong\u003e2200494.\u003c/li\u003e\n\u003cli\u003eYe Y: China\u0026apos;s rolling COVID waves could hit every six months - infecting millions\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eNature \u003c/em\u003e2023, 618\u003cstrong\u003e:\u003c/strong\u003e442-443.\u003c/li\u003e\n\u003cli\u003eAta B, Vermeulen N, Mocanu E, Gianaroli L, Lundin K, Rautakallio-Hokkanen S, Tapanainen JS, Veiga A: SARS-CoV-2, fertility and assisted reproduction\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eHum Reprod Update \u003c/em\u003e2023, 29\u003cstrong\u003e:\u003c/strong\u003e177-196.\u003c/li\u003e\n\u003cli\u003eHoffmann M, Kleine-Weber H, Schroeder S, Kr\u0026uuml;ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eCell \u003c/em\u003e2020, 181\u003cstrong\u003e:\u003c/strong\u003e271-280.e278.\u003c/li\u003e\n\u003cli\u003eWang Y, Wang Y, Luo W, Huang L, Xiao J, Li F, Qin S, Song X, Wu Y, Zeng Q, et al: A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eInt J Med Sci \u003c/em\u003e2020, 17\u003cstrong\u003e:\u003c/strong\u003e1522\u0026ndash;1531.\u003c/li\u003e\n\u003cli\u003eStanley KE, Thomas E, Leaver M, Wells D: Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFertil Steril \u003c/em\u003e2020, 114\u003cstrong\u003e:\u003c/strong\u003e33-43.\u003c/li\u003e\n\u003cli\u003eHenarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A, Pellicer A, Diaz-Gimeno P: SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFertil Steril \u003c/em\u003e2020, 114\u003cstrong\u003e:\u003c/strong\u003e223-232.\u003c/li\u003e\n\u003cli\u003eEssahib W, Verheyen G, Tournaye H, Velde HVD: SARS-CoV-2 host receptors ACE2 and CD147 (BSG) are present on human oocytes and blastocysts\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2020, 37\u003cstrong\u003e:\u003c/strong\u003e2657\u0026ndash;2660.\u003c/li\u003e\n\u003cli\u003eWeatherbee BAT, Glover DM, Zernicka-Goetz M: Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eOpen Biol \u003c/em\u003e2020, 10\u003cstrong\u003e:\u003c/strong\u003e200162.\u003c/li\u003e\n\u003cli\u003eVirant-Klun I, Strle F: Human Oocytes Express Both ACE2 and BSG Genes and Corresponding Proteins: Is SARS-CoV-2 Infection Possible? \u003cem\u003eStem Cell Rev Rep \u003c/em\u003e2021, 17\u003cstrong\u003e:\u003c/strong\u003e278-284.\u003c/li\u003e\n\u003cli\u003eYoungster M, Avraham S, Yaakov O, Landau Rabbi M, Gat I, Yerushalmi G, Sverdlove R, Baum M, Maman E, Hourvitz A, Kedem A: IVF under COVID-19: treatment outcomes of fresh ART cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eHum Reprod \u003c/em\u003e2022, 37\u003cstrong\u003e:\u003c/strong\u003e947-953.\u003c/li\u003e\n\u003cli\u003eOrvieto R, Segev-Zahav A, Aizer A: Does COVID-19 infection influence patients\u0026apos; performance during IVF-ET cycle?: an observational study\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eGynecol Endocrinol \u003c/em\u003e2021, 37\u003cstrong\u003e:\u003c/strong\u003e895-897.\u003c/li\u003e\n\u003cli\u003eHerrero Y, Pascuali N, Vel\u0026aacute;zquez C, Oubi\u0026ntilde;a G, Hauk V, de Z\u0026uacute;\u0026ntilde;iga I, Pe\u0026ntilde;a MG, Mart\u0026iacute;nez G, Lavolpe M, Veiga F, et al: SARS-CoV-2 infection negatively affects ovarian function in ART patients\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eBiochim Biophys Acta Mol Basis Dis \u003c/em\u003e2022, 1868\u003cstrong\u003e:\u003c/strong\u003e166295.\u003c/li\u003e\n\u003cli\u003eWang M, Hu J, Huang B, Yang Q, Liu S, Li Z, Yang L, Xi Q, Zhu L, Jin L: Investigating the impact of SARS-CoV-2 infection on basic semen parameters and in vitro fertilization/intracytoplasmic sperm injection outcomes: a retrospective cohort study\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eReprod Biol Endocrinol \u003c/em\u003e2022, 20\u003cstrong\u003e:\u003c/strong\u003e46.\u003c/li\u003e\n\u003cli\u003eDemirel C, Tulek F, Celik HG, Donmez E, Tuysuz G, G\u0026ouml;kcan B: Failure to Detect Viral RNA in Follicular Fluid Aspirates from a SARS-CoV-2-Positive Woman\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eReprod Sci \u003c/em\u003e2021, 28\u003cstrong\u003e:\u003c/strong\u003e2144-2146.\u003c/li\u003e\n\u003cli\u003eBoudry L, Essahib W, Mateizel I, Velde HVD, De Geyter D, Pi\u0026eacute;rard D, Waelput W, Uvin V, Tournaye H, De Vos M, De Brucker M: Undetectable viral RNA in follicular fluid, cumulus cells, and endometrial tissue samples in SARS-CoV-2-positive women\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFertil Steril \u003c/em\u003e2022, 117\u003cstrong\u003e:\u003c/strong\u003e771\u0026ndash;780.\u003c/li\u003e\n\u003cli\u003eLiu P, Xu J: Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022\u0026ndash;January 2023\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Infect \u003c/em\u003e2023, 86\u003cstrong\u003e:\u003c/strong\u003ee84\u0026ndash;86.\u003c/li\u003e\n\u003cli\u003eZeng X, Xie Y, Yang X, Peng Z, Tang J, Yang L, Lin S, Han J, Zhang Y, Wang D: SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eChina CDC Wkly \u003c/em\u003e2023, 5\u003cstrong\u003e:\u003c/strong\u003e152-158.\u003c/li\u003e\n\u003cli\u003eSun Y, Wang M, Lin W, Dong W, Xu J: Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Biosaf Biosecur \u003c/em\u003e2023, 5\u003cstrong\u003e:\u003c/strong\u003e14\u0026ndash;20.\u003c/li\u003e\n\u003cli\u003eVeeck LL: Oocyte assessment and biological performance\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eAnn N Y Acad Sci \u003c/em\u003e1988, 541\u003cstrong\u003e:\u003c/strong\u003e259\u0026ndash;274.\u003c/li\u003e\n\u003cli\u003eGardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB: Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFertil Steril \u003c/em\u003e2000, 73\u003cstrong\u003e:\u003c/strong\u003e1155-1158.\u003c/li\u003e\n\u003cli\u003eLiu L, Li YH, Ding XF, Geng YH, Chen CY, Gao Y: Influence of blastocysts morphological score on pregnancy outcomes in frozen-thawed blastocyst transfers: a retrospective study of 741 cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Huazhong Univ Sci Technolog Med Sci \u003c/em\u003e2014, 34\u003cstrong\u003e:\u003c/strong\u003e750-754.\u003c/li\u003e\n\u003cli\u003eGandhi RT, Lynch JB, Del RC: Mild or moderate covid-19\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eN Engl J Med \u003c/em\u003e2020, 383\u003cstrong\u003e:\u003c/strong\u003e1757\u0026ndash;1766.\u003c/li\u003e\n\u003cli\u003eBerlin DA, Gulick RM, Martinez FJ: Severe Covid-19\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eN Engl J Med \u003c/em\u003e2020, 383\u003cstrong\u003e:\u003c/strong\u003e2451-2460.\u003c/li\u003e\n\u003cli\u003eBlock LN, Aliota MT, Friedrich TC, Schotzko ML, Mean KD, Wiepz GJ, Golos TG, Schmidt JK: Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model\u0026dagger;\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eBiol Reprod \u003c/em\u003e2020, 102\u003cstrong\u003e:\u003c/strong\u003e806-816.\u003c/li\u003e\n\u003cli\u003eCarbone L, Conforti A, A. MAL, Cariati F, Vallone R, Raffone A, Buonfantino C, Palese M, Mascia M, I. GRD, et al: The negative impact of most relevant infections on fertility and assisted reproduction technology\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eMinerva Obstet Gynecol \u003c/em\u003e2021, 74\u003cstrong\u003e:\u003c/strong\u003e83\u0026ndash;106.\u003c/li\u003e\n\u003cli\u003eKabalkin Y, Bentov Y, Gil M, Beharier O, Jaber S, Moav-Zafrir A, Khwies D, Ben-Meir A, Esh Broder E, Walfisch A, et al: Mild COVID-19 was not associated with impaired IVF outcomes or early pregnancy loss in IVF patients\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Clin Med \u003c/em\u003e2022, 11\u003cstrong\u003e:\u003c/strong\u003e5265.\u003c/li\u003e\n\u003cli\u003eHuri M, Noferi V, Renda I, Piazzini F, Benemei S, Coccia ME: The COVID-19 Pandemic Impact on the Outcome of Medically Assisted Reproduction Pregnancies\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFront Reprod Health \u003c/em\u003e2022, 4\u003cstrong\u003e:\u003c/strong\u003e860425.\u003c/li\u003e\n\u003cli\u003eAlbeitawi S, Al-Alami ZM, Hamadneh J, Alqam H, Qublan H, Al Natsheh M: COVID-19 infection and vaccine have no impact on in-vitro fertilization (IVF) outcome\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eSci Rep \u003c/em\u003e2022, 12\u003cstrong\u003e:\u003c/strong\u003e21702.\u003c/li\u003e\n\u003cli\u003eRageh KEA, Farag EA, Behery MA, Badreldin MA, Ali EA: The Impact of Previous Exposure to COVID-19 on the Outcome of ICSI Cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJBRA Assist Reprod \u003c/em\u003e2023.\u003c/li\u003e\n\u003cli\u003eYoungster M, Avraham S, Yaakov O, Rabbi ML, Gat I, Yerushalmi G, Baum M, Maman E, Hourvitz A, Kedem A: The impact of past COVID-19 infection on pregnancy rates in frozen embryo transfer cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2022, 39\u003cstrong\u003e:\u003c/strong\u003e1565\u0026ndash;1570.\u003c/li\u003e\n\u003cli\u003eESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine: The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eHum Reprod Open \u003c/em\u003e2017, 2017\u003cstrong\u003e:\u003c/strong\u003ehox011.\u003c/li\u003e\n\u003cli\u003eRomanski PA, Aluko A, Bortoletto P, Elias R, Rosenwaks Z: Age-specific blastocyst conversion rates in embryo cryopreservation cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eReprod Biomed Online \u003c/em\u003e2022, 45\u003cstrong\u003e:\u003c/strong\u003e432-439.\u003c/li\u003e\n\u003cli\u003eBraga DP, Setti AS, Figueira RC, Machado RB, Iaconelli A, Jr., Borges EJ: Influence of oocyte dysmorphisms on blastocyst formation and quality\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eFertil Steril \u003c/em\u003e2013, 100\u003cstrong\u003e:\u003c/strong\u003e748\u0026ndash;754.\u003c/li\u003e\n\u003cli\u003ePiccolomini MM, Bonetti TC, Motta E, Serafini PC, Alegretti JR: How general semen quality influences the blastocyst formation rate: Analysis of 4205 IVF cycles\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJBRA Assist Reprod \u003c/em\u003e2018, 22\u003cstrong\u003e:\u003c/strong\u003e89-94.\u003c/li\u003e\n\u003cli\u003eLoutradi KE, Tarlatzis BC, Goulis DG, Zepiridis L, Pagou T, Chatziioannou E, Grimbizis GF, Papadimas I, Bontis I: The effects of sperm quality on embryo development after intracytoplasmic sperm injection\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2006, 23\u003cstrong\u003e:\u003c/strong\u003e69-74.\u003c/li\u003e\n\u003cli\u003eChen X, Shi H, Li C, Zhong W, Cui L, Zhang W, Geng L, Hu K, Fang M, Wei D, et al: The effect of SARS-CoV-2 infection on human embryo early development: a multicenter prospective cohort study\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eSci China Life Sci \u003c/em\u003e2023, 66\u003cstrong\u003e:\u003c/strong\u003e1697\u0026ndash;1700.\u003c/li\u003e\n\u003cli\u003eWilkins J, Al-Inizi S: Premature ovarian insufficiency secondary to COVID-19 infection: An original case report\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eInt J Gynaecol Obstet \u003c/em\u003e2021, 154\u003cstrong\u003e:\u003c/strong\u003e179-180.\u003c/li\u003e\n\u003cli\u003eLuongo FP, Dragoni F, Boccuto A, Paccagnini E, Gentile M, Canosi T, Morgante G, Luddi A, Zazzi M, Vicenti I, Piomboni P: SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eCells \u003c/em\u003e2022, 11.\u003c/li\u003e\n\u003cli\u003eColaco S, Chhabria K, Singh D, Bhide A, Singh N, Singh A, Husein A, Mishra A, Sharma R, Ashary N, Modi D: Expression map of entry receptors and infectivity factors for pan-coronaviruses in preimplantation and implantation stage human embryos\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2021, 38\u003cstrong\u003e:\u003c/strong\u003e1709-1720.\u003c/li\u003e\n\u003cli\u003eMontano M, Victor AR, Griffin DK, Duong T, Bolduc N, Farmer A, Garg V, Hadjantonakis AK, Coates A, Barnes FL, et al: SARS-CoV-2 can infect human embryos\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eSci Rep \u003c/em\u003e2022, 12\u003cstrong\u003e:\u003c/strong\u003e15451.\u003c/li\u003e\n\u003cli\u003eBhayana DP, Raja KA, Chitra J, Sonu B: Failure to Detect Viral Ribonucleic Acid in Follicular Fluid of a Severe Acute Respiratory Syndrome Coronavirus 2-Infected Female - A Report from the Indian Subcontinent\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Hum Reprod Sci \u003c/em\u003e2022, 15\u003cstrong\u003e:\u003c/strong\u003e396-398.\u003c/li\u003e\n\u003cli\u003eBarragan M, Guill\u0026eacute;n JJ, Martin-Palomino N, Rodriguez A, Vassena R: Undetectable viral RNA in oocytes from SARS-CoV-2 positive women\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eHum Reprod \u003c/em\u003e2021, 36\u003cstrong\u003e:\u003c/strong\u003e390-394.\u003c/li\u003e\n\u003cli\u003eBurke CA, Skytte AB, Kasiri S, Howell D, Patel ZP, Trolice MP, Parekattil SJ, Michael SF, Paul LM: A cohort study of men infected with COVID-19 for presence of SARS-CoV-2 virus in their semen\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2021, 38\u003cstrong\u003e:\u003c/strong\u003e785-789.\u003c/li\u003e\n\u003cli\u003eGaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, et al: Evolution of antibody immunity to SARS-CoV-2\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eNature \u003c/em\u003e2021, 591\u003cstrong\u003e:\u003c/strong\u003e639-644.\u003c/li\u003e\n\u003cli\u003eTay MZ, Poh CM, R\u0026eacute;nia L, MacAry PA, Ng LFP: The trinity of COVID-19: immunity, inflammation and intervention\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eNat Rev Immunol \u003c/em\u003e2020, 20\u003cstrong\u003e:\u003c/strong\u003e363-374.\u003c/li\u003e\n\u003cli\u003eXie Y, Mirzaei M, Kahrizi MS, Shabestari AM, Riahi SM, Farsimadan M, Roviello G: SARS-CoV-2 effects on sperm parameters: a meta-analysis study\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eJ Assist Reprod Genet \u003c/em\u003e2022, 39\u003cstrong\u003e:\u003c/strong\u003e1555\u0026ndash;1563.\u003c/li\u003e\n\u003cli\u003eLi K, Chen G, Hou H, Liao Q, Chen J, Bai H, Lee S, Wang C, Li H, Cheng L, Ai J: Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eReprod Biomed Online \u003c/em\u003e2021, 42\u003cstrong\u003e:\u003c/strong\u003e260-267.\u003c/li\u003e\n\u003cli\u003eDepuydt C, Bosmans E, Jonckheere J, Donders F, Ombelet W, Coppens A, Donders G: SARS-CoV-2 infection reduces quality of sperm parameters: prospective one year follow-up study in 93 patients\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eEBioMedicine \u003c/em\u003e2023, 93\u003cstrong\u003e:\u003c/strong\u003e104640.\u003c/li\u003e\n\u003cli\u003eMiller JE, Smith TT: The effect of intracytoplasmic sperm injection and semen parameters on blastocyst development in vitro\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eHum Reprod \u003c/em\u003e2001, 16\u003cstrong\u003e:\u003c/strong\u003e918-924.\u003c/li\u003e\n\u003cli\u003eWu J, Liang B, Chen C, Wang H, Fang Y, Shen S, Yang X, Wang B, Chen L, Chen Q, et al: SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19\u003cstrong\u003e.\u003c/strong\u003e \u003cem\u003eNat Commun \u003c/em\u003e2021, 12\u003cstrong\u003e:\u003c/strong\u003e1813.\u003c/li\u003e\n\u003cli\u003eHan J, Zhang N, Chen D, Gong Y, Li G, Kong Y, Pu L, Chen C, Liu J, Wang Q, et al: Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity\u003cstrong\u003e.\u003c/strong\u003e\u003cem\u003eSci China Life Sci \u003c/em\u003e2022, 65\u003cstrong\u003e:\u003c/strong\u003e223-226.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1.\u003c/strong\u003e Baseline characteristics of the women in the infected and uninfected groups before and after matching\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.74969623329283%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517618469015794%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBefore propensity score matching\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"39.732685297691376%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eAfter propensity score matching\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCharacteristic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003eUninfected group\u003c/p\u003e\n \u003cp\u003e(n=2,660）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003eInfected group\u003c/p\u003e\n \u003cp\u003e(n=386)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003eUninfected group\u003c/p\u003e\n \u003cp\u003e(n=698)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003eInfected group\u003c/p\u003e\n \u003cp\u003e(n=358)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u0026nbsp;\u003c/em\u003evalue\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eAge of the woman (y)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e32 (29, 35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e33 (30, 35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.004\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e32 (30,35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e33 (30,35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.631\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eInfertility duration (y)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e3 (1.5, 4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e3 (1.5, 4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.971\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e3 (1.5, 4.13）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e3 (1.5, 4.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.951\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003ePrimary infertility, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e1359 (51.09%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e190 (49.22%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.493\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e350 (50.14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e189 (52.79%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.415\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eCycle number, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.221\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.158\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eFirst cycle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e2106 (79.17%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e316 (81.87%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e609 (87.25%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e301 (84.08%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eRepeated cycles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e554 (20.83)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e70 (18.13%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e89 (12.75%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e57 (15.92%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eAMH (ng/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e3.07 (1.70, 5.25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e3.24 (1.92, 5.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.132\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e3.42 (1.87, 6.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e3.23 (1.94, 5.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.319\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eBasal FSH level (IU/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e7.19 (5.94, 8.74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e7.21 (5.77, 8.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.487\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e7.02 (5.87, 8.47)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e7.10 (5.70, 8.64)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.100\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eBody mass index (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e22.50 (20.43,25.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e22.84 (20.99, 24.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.177\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e22.65 (20.66, 25.23)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e22.83 (20.99, 24.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.610\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eCause of infertility, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.006\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.955\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eTubal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e997(37.48%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e143 (37.05%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e260 (37.25%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e138 (38.55%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" rowspan=\"7\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eMale factor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e205(7.71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e32 (8.29%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e54 (7.74%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e28 (7.82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eAnovulatory\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e285(10.71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e33 (8.55%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e67 (9.60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e33 (9.22%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eUnexplained\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e640(24.06%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e99 (25.65%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e197 (28.22%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e96 (26.82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eDiminished ovarian reserve\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e345(12.97%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e44 (11.40%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e79 (11.32%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e38 (10.61%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eEndometriosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e162(6.09%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e22 (5.70%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e31 (4.44%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e21 (5.87%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eMixed factors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e26(0.98%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e13 (3.37%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e10 (1.43%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e4 (1.12%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eOS protocol, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.809\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eGnRH-agonist\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e1153 (43.35%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e93 (24.09%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e175 (25.07%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e93 (25.98%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" rowspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eGnRH-antagonist\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e863 (32.44%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e226 (58.55%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e393 (56.30%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e204 (56.98%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.614775725593667%\" valign=\"top\"\u003e\n \u003cp\u003eCPOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.226912928759894%\" valign=\"top\"\u003e\n \u003cp\u003e644 (24.21%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.75461741424802%\" valign=\"top\"\u003e\n \u003cp\u003e67 (17.36%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.970976253298153%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.337730870712402%\" valign=\"top\"\u003e\n \u003cp\u003e130 (18.62%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.094986807387862%\" valign=\"top\"\u003e\n \u003cp\u003e61 (17.04%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eInsemination method, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.099\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.681\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eIVF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e1828 (68.72%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e280 (72.54%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e499 (71.49%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e265 (74.02%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eICSI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e709 (26.65%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e84 (21.76%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e153 (21.92%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e72 (20.11%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eIVF+RICSI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e123 (4.62%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e22 (5.70%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e46 (6.59%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e21 (5.87%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eGonadotropins dosage (IU)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e2325 (1800, 2925)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e2250 (1819, 2700)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.061\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e2300 (1800, 2850)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e2250 (1800, 2700)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.415\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eGn duration, d\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e9 (8, 11)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e9 (8, 10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e9 (8, 10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e9 (8,10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.161\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eE2 on trigger day, pg/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e2047(1188,3362)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e1720(1108, 2731)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e1726(973.2. 2976)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e1752(1117, 2760)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.864\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"21.696969696969695%\" valign=\"top\"\u003e\n \u003cp\u003eEndometrial thickness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e10(8,12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.393939393939394%\" valign=\"top\"\u003e\n \u003cp\u003e10(8,12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.242424242424242%\" valign=\"top\"\u003e\n \u003cp\u003e0.511\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.848484848484848%\" valign=\"top\"\u003e\n \u003cp\u003e10(8,12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.787878787878787%\" valign=\"top\"\u003e\n \u003cp\u003e10(8,12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.121212121212121%\" valign=\"top\"\u003e\n \u003cp\u003e0.509\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u0026nbsp;\u003c/strong\u003eData are presented as the median (25th and 75th percentile) or number (%). Mann‒Whitney U statistics were used for continuous variables and chi-square tests were used for categorical variables. There were no significant differences after propensity score matching. AMH, anti-M\u0026uuml;llerian hormone; FSH, follicle-stimulating hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2, Estradiol.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2.\u003c/strong\u003e Embryo laboratory outcomes after matching\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"704\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\"\u003e\n \u003cp\u003eUninfected group\u003c/p\u003e\n \u003cp\u003e(n=698)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\"\u003e\n \u003cp\u003eInfected group\u003c/p\u003e\n \u003cp\u003e(n=358)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u0026nbsp;\u003c/em\u003evalue\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\"\u003e\n \u003cp\u003e95% CI\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eAverage no. of oocytes retrieved\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e11 (6, 16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e11(6, 17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e-1.00-1.00）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eMature oocyte rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e84.81 (71.43, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e82.35(69.23, 94.12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.138\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e-0.03-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eNormal fertilization rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e57.14 (40.00, 75.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e56.25 (40.00, 71.43)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.501\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e-0.04-0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eAbnormal fertilization rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e0.00 (0.00, 12.50）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e0.00 (0.00, 14.29)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.840\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e0.00-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eCleavage rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e100 (100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e100 (100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.659\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e0.00-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eHigh-quality embryo rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e37.50(11.46, 64.12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e44.44 (20.00, 66.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.052\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e0.00-0.08\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eBlastocyst formation rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e73.33(50.00, 92.31）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e66.67 (50.00, 87.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e-0.08-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.6875%\" valign=\"bottom\"\u003e\n \u003cp\u003eAvailable blastocyst rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.306818181818183%\" valign=\"top\"\u003e\n \u003cp\u003e62.50 (45.45, 80.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.75%\" valign=\"top\"\u003e\n \u003cp\u003e60.00 (40.00, 80.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.795454545454545%\" valign=\"top\"\u003e\n \u003cp\u003e0.438\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.460227272727273%\" valign=\"top\"\u003e\n \u003cp\u003e--0.05-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eOR, Odds ratio; CI, confidence interval.\u003c/p\u003e\n\u003cp\u003eContinuous variables are presented as the median (25th and 75th percentile), while categorical variables are presented as the % (n); P \u0026lt; 0.05 was considered statistically significant.\u003c/p\u003e\n\u003cp\u003eMature oocyte rate = Total number of mature oocytes/the total number of oocytes retrieved \u0026times;100%.\u003c/p\u003e\n\u003cp\u003e2PN fertilization rate =D1 number of 2PN oocyte/(total number of IVF fertilized oocytes + total number of MII oocytes injected) \u0026times;100%.\u003c/p\u003e\n\u003cp\u003eD3 high-quality embryo rate =D3 high quality embryo number/normal fertilization cleavage embryo number \u0026times;100%.\u003c/p\u003e\n\u003cp\u003eBlastocyst formation rate = the number of blastocysts formed/the number of Day 3 embryos for extended culture.\u003c/p\u003e\n\u003cp\u003eAvailable blastocyst rate = the number of blastocysts available for cryopreservation/the number of Day 3 embryos available for extended culture.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3.\u003c/strong\u003e Subgroup analysis based on the time interval from SARS-CoV-2 infection to oocyte retrieval\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"874\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eCharacteristic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026le;30 d(n=69)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u003cstrong\u003e31~60 d (n=69)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u003cstrong\u003e61~90 d (n=119)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e\u003cstrong\u003e＞\u003c/strong\u003e\u003cstrong\u003e90 d (n=101)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u0026nbsp;\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003evalue\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge of the woman (y)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e32(29, 34)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e32(30, 36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e33(30, 35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e33(30, 35.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.710\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInfertility duration (y)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e3.00(1.00, 3.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e2.00(2.00, 4.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e3.00(1.00, 5.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e3.00(2.00, 5.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.302\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePrimary infertility, n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e31(44.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e34(49.28)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e56(47.06)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e56(55.45)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.514\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eCycle number, n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eFirst cycle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e59(85.51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e56(81.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e101(84.87)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e85(84.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.896\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eRepeated cycles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e10(14.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e13(18.84)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e18(15.13)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e16(15.84)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.896\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAMH (ng/ml)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e3.49(1.79, 6.11)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e3.56(2.03, 4.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e3.31(1.95, 5.36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e2.93(1.65, 4.73)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.561\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eBasal FSH level (IU/L)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e6.74(5.33, 8.91)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e6.84(5.47, 8.41)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e6.97(5.87, 8.60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e7.48(6.21, 8.75)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.171\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eBody mass index (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e22.70(20.83, 24.35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e23.02(21.29, 24.83)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e22.84(21.18, 25.62)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e22.73(20.78, 24.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.536\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eCause of infertility, n(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eTubal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e31(44.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e26(37.68)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e39(32.77)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e43(42.57)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.251\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eMale factor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e4(5.80)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e3(4.35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e12(10.08)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e9(8.91)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.465\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eAnovulatory\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e8(11.59)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e7(10.15)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e13(10.92)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e5(4.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.369\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eUnexplained\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e15(21.74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e23(33.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e28(23.53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e29(28.71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.355\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eDiminished ovarian reserve\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e8(11.59)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e5(7.25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e15(12.61)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e9(8.91)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.635\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eEndometriosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e3(4.35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e5(7.25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e9(7.56)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e5(4.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.635\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eMixed factors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e0.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e3(2.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e1(0.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.460\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eOS protocol, n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e＜0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eGnRH-agonist\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e23(33.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e19(27.54)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e24(20.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e27(26.73)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eGnRH-antagonist\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e30(43.48)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e32(46.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e73(61.35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e69(68.32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eCPOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e16(23.19)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e18(26.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e22(18.49)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e5(4.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInsemination method, n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.009\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eIVF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e44(63.77)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e42(60.87)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e94(80.34)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e83(83.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eICSI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e19(27.54)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e20(28.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e18(15.39)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e14(14.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003eIVF+RICSI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e6(8.70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e7(10.15)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e5(4.27)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e3(3.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGonadotropins dosage (IU)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e2175(1750,2888)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e2325(1950,2663)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e2175(1800,2700)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e2250(1813,2700)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.628\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGn duration, d\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e9(8,10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e9(8,10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e9(8,10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e9(8,10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.576\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eE2 on trigger day (pg/mL)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e2037(1310,3281)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e1860(1179,2705)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e1681(1087,2570)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e1622(984.9,2683)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.075\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAverage no. of oocytes retrieved\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e10.00(6.00, 16.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e10.00(6.00, 17.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e12.00(6.00, 17.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e11.00(6.00, 17.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.986\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eMature oocyte rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e0.81(0.70, 0.91）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0.83(0.67, 0.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0.83(.72, 0.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e0.82(0.67,1.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.814\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNormal fertilization rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e0.53(0.37,0.70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0.58(0.38, 0.73)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0.60(0.46, 0.72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e0.54(0.39, 0.75)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.278\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAbnormal fertilization rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e0(0, 15.04)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0(0, 12.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e5.13(0, 13.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e5.28(0, 15.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.331\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eCleavage rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e100(100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e100(100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e100(100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e100(100, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.654\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHigh-quality embryo rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e50.00(33.33, 65.91)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e33.33(0, 53.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e50.00(29.64, 66.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e45.56(15.42, 66.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.011\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eBlastocyst formation rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e73.68(50.00, 100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e50.00(31.67, 83.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e69.23(55.56, 87.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e66.67(50.00, 83.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.012\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAvailable blastocyst rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e66.67(50.00, 89,44)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e50.00(20.00, 71.71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e66.67(50.00, 81.82)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e60.00(40.00, 72.32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.003\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHigh-quality blastocyst rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e0(0, 28.57)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e0(0, 29.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e20.00(0, 40.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e3.57(0, 42.14)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.109\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eImplantation rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e56.94（41/72）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e57.63（34/59）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e56.44（57/101）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e48.24（41/85）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.593\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eBiochemical pregnancy rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e70.97（44/62）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e75.93（41/54）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e67.35（66/98）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e64.47（49/76）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.537\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eClinical pregnancy rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e61.29（38/62）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e62.96（34/54）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e58.16（57/98）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e53.95（41/76）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.730\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.856815578465064%\"\u003e\n \u003cp\u003e\u003cstrong\u003eEarly pregnancy loss rate, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.265750286368842%\"\u003e\n \u003cp\u003e13.16（5/38）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e5.88（2/34）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.120274914089347%\"\u003e\n \u003cp\u003e15.79（9/57）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.463917525773196%\"\u003e\n \u003cp\u003e7.32（3/41）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.172966781214203%\"\u003e\n \u003cp\u003e0.430\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eNote: Data are presented as the median (25th and 75th percentile) or number (%). Mann‒Whitney U statistics were used for continuous variables and chi-square tests were used for categorical variables. AMH, anti-M\u0026uuml;llerian hormone; FSH, follicle-stimulating hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2, Estradiol.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4.\u003c/strong\u003e Linear regression analysis of the variables for the blastocyst formation rate based on the SARS-CoV-2 infection interval\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"873\" height=\"811\"\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003eAMH, anti-M\u0026uuml;llerian hormone; OS, ovarian stimulation; CPOS, clomiphene-primed ovarian stimulation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; RICSI, early rescue intracytoplasmic sperm injection; E2.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5.\u003c/strong\u003e Clinical outcomes after the first cycle of embryo transfer after matching\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003eUninfected group\u003c/p\u003e\n \u003cp\u003e(n=698)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003eInfected group\u003c/p\u003e\n \u003cp\u003e(n=358)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003eZ value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003ep value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003eOR (95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eSingle embryo transfer rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e85.67 (520/607)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e88.62(257/290)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e1.215\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.224\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e0.76(0.50-1.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eEmbryo transfer strategies, n(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.4026\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.687\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e0.94(0.70-1.26)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eFresh embryo transfer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e199 (32.78)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e99 (34.14)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eFrozen embryo transfer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e408 (67.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e191 (65.86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eImplantation rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e54.32 (377/694)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e53.87 (174/323)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.1349\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.893\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e1.02(0.78-1.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eBiochemical pregnancy rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e65.57 (398/607)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e68.62 (199/290)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.906\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.365\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e0.87(0.65-1.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eClinical pregnancy rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e57.00 (346/607)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e58.62 (170/290)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.4588\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e0.94(0.70-1.24)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eEarly pregnancy loss rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e10.98 (38/346)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e10.59 (18/170)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.1354\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.892\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e1.04(0.57-1.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eEctopic pregnancy rate, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e1.15 (4/346)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e/\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.307\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e0.00(0.00-2.04)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.003359462486003%\"\u003e\n \u003cp\u003eNo available embryo cycle rate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.141097424412095%\"\u003e\n \u003cp\u003e9.60 (67/698)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.02127659574468%\"\u003e\n \u003cp\u003e8.04 (32/398)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.630459126539753%\"\u003e\n \u003cp\u003e0.8657\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.638297872340425%\"\u003e\n \u003cp\u003e0.387\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.565509518477043%\"\u003e\n \u003cp\u003e1.21(0.79-1.88)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"COVID-19, IVF, SARS-CoV-2, infertility, embryo, pregnancy","lastPublishedDoi":"10.21203/rs.3.rs-3172915/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3172915/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground: \u003c/strong\u003eThe SARS-CoV-2 virus is continually evolving, and the worldwide epidemic is still ongoing. There is conflicting evidence regarding how SAS-CoV-2 infection affects the outcomes of assisted reproductive technology (ART).\u003cstrong\u003e \u003c/strong\u003eThe aim of the current study was to investigate whether the outcomes of in vitro fertilization (IVF) treatment were affected during the acute period of SARS-CoV-2 infection or immediately after recovery from COVID-19.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eIn this retrospective cohort study, SARS-CoV-2-infected couples who underwent IVF treatment at Wuhan Union Hospital within the first three months following the lifting of the pandemic policy in mainland China were propensity-score matched (PSM) to uninfected couples who received IVF during the dynamic COVID-zero policy. Following matching, 358 and 698 patients were assigned to the SARS-CoV-2-infected and uninfected groups, respectively. The laboratory and clinical outcomes of the two groups were compared.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eThe average number of oocytes retrieved, mature oocyte rates, normal fertilization rates, abnormal fertilization rates, and cleavage rates did not differ significantly between the two groups. The blastocyst formation rates were considerably lower in the infected group than in the uninfected group. Stratification by time from SARS-CoV-2 infection to oocyte retrieval (≤ 30, 31-60, 61-90 and ≥90 days) revealed that both blastocyst formation and available blastocyst rates were significantly decreased when oocyte retrieval was performed 31-60 days after SARS-CoV-2 infection. However, after the first embryo transfer cycle, there were no significant differences in the rates of embryo implantation, biochemical pregnancy, clinical pregnancy or early abortion between the two matched cohorts.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e SARS-CoV-2 infection had no effect on clinical outcomes after the first embryo transfer cycle; however, the blastocyst formation rate was significantly lower in couples who underwent IVF treatment 31-60 days after SARS-CoV-2 infection, indicating that SARS-CoV-2 infection may still impair embryo developmental potential.\u003c/p\u003e","manuscriptTitle":"Effect of SARS-CoV-2 infection on IVF/ICSI-ET outcomes: A propensity score-matched cohort study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-07-21 19:48:51","doi":"10.21203/rs.3.rs-3172915/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2e2d4bae-edf0-41b4-8ec6-897282259db1","owner":[],"postedDate":"July 21st, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-08-26T07:44:16+00:00","versionOfRecord":[],"versionCreatedAt":"2023-07-21 19:48:51","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3172915","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3172915","identity":"rs-3172915","version":["v1"]},"buildId":"ehx78VzkSd0WSzXnipQa-","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}